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ABSTRACT 
Previous epidemiological and experimental studies have strongly implicated estrogens 
in breast cancer risk and Estrogen Receptor (ER), the transcription factor to which 
estrogen binds, is considered as the major molecular driver of around 70% breast 
cancers. The importance of the deregulated estrogen signalling is further highlighted 
by increasing evidence that current chemopreventive and therapeutic strategies that 
target hormonally responsive breast cancers frequently result in the development of 
resistance to anti-estrogens and metastatic progression, highlighting the need for 
understanding the molecular underlying mechanisms. While until recently, ER was 
believed to act as a stand-alone transcription factor, which can directly bind its motifs 
in DNA, it is now accepted that ER activity is a complex and dynamic process that 
requires highly concerted actions of a dozen transcriptional cofactors and various 
chromatin regulators at DNA. Recent studies focused on characterising ER-associated 
cofactors and their role in opening the chromatin provided a remarkable insight into 
transcriptional regulation mediated by ER. However DNA methylation and histone 
acetylation are poorly understood in the context of ER’s dynamic binding. 
In this thesis, I combined a cell culture protocol adapted for studying estradiol (E2) 
deprivation and re-stimulation in stricto sensu in ER-positive breast cancer cells with 
the latest methylation array, that allowed a genome-wide interrogation of DNA 
methylation (including a comprehensive panel of enhancers). I further investigated 
histone acetylation (ChIP-seq) and transcriptome (RNA-seq) after E2 deprivation and 
re-stimulation to better characterise the ability of ER to coordinate gene regulation. I 
found that E2 deprivation and re-stimulation result in time-dependent DNA 
methylation changes and in histone acetylation across diverse genomic regions, many 
of which overlap with enhancers. Further enrichment analysis of transcription factor 
(TF) binding and motif occurrence highlights the importance of ER tethering mainly 
through two partner TF families, AP-1 and FOX, in the proximity of enhancers that 
are differentially methylated and acetylated. This is the first study that 
comprehensively characterized DNA methylation at enhancers in response to 
inhibition and activation of ER signalling. The transcriptome and genome occupancy 
data further reinforced the notion that ER activity may orchestrate a broad 
transcriptional programme through regulating a limited panel of critical enhancers. 
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Finally, the E2 re-stimulation experiments revealed that although the majority of the 
observed epigenetic changes induced by E2 deprivation could be largely reversed 
when the cells were re-stimulated we show that DNA hypermethylation and H3K27 
acetylation at enhancers as well as several gene expression changes are selectively 
retained. The partial reversibility can be interpreted as a sign of treatment efficiency 
but also as a mechanism by which ER activity may contribute to endocrine resistance. 
This study provides entirely new information that constitutes a major advance in our 
understanding of the events by which ER and its cofactors mediate changes in DNA 
methylation and chromatin states at enhancers. These findings should open new 
avenues for studying role of the deregulated estrogen signalling in the mechanism 
underlying the “roots” of endocrine resistance that commonly develops in response to 
anti-estrogen therapy. 
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INTRODUCTION 
1. Breast cancer epidemiology 
Despite the continuous efforts for prevention and surveillance, breast cancer (BC) 
remains the most common cancer in women across the world with an incidence 
ranging from 26 to 95 cases per 100,000 individuals (Figure 1) (Bray et al., 2018). A 
small proportion of this incidence is explained by genetic predisposition attributed to 
family history and ethnicity, but BC is mostly a cancer associated to socioeconomic 
status and lifestyle practices characteristic of high-income countries (Choi et al., 
2018; Kuchenbaecker et al., 2017; Lundqvist et al., 2016). Indeed, alcohol intake, 
reproductive factors, high-calorie diet, weight and lack of physical activity, are all 
factors that increase the risk of BC (Schnitt and Lakhani, 2014). In addition to these, 
intake of estrogen-progestogen contraceptives and menopausal therapies as well as 
involuntary exposure to endocrine disruptive chemicals in critical developmental 
windows can disturb hormonal signalling and contribute to oncogenesis (Rodgers et 
al., 2018). Mortality rates are lesser compared to incidence rates and also more evenly 
spread worldwide while they have been decreasing in high-income countries 
reflecting a discrepancy in healthcare systems (Lundqvist et al., 2016). 
Figure 1. Worldwide age-standardised incidence rates of breast cancer in 2018 (ASR: Age-
standardised rate)1. 
 
       
1  Data source: GLOBOCAN 2018; graph production: International Agency for 
Research on Cancer (http://gco.iarc.fr/today) 
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2. Adult mammary gland and molecular BC subtypes 
The functional unit of breast is the mammary gland, which is build of a network of 
ducts and alveoli engulfed in stromal cells that are mostly adipocytes (Figure 2) 
(Visvader and Stingl, 2014). The luminal fraction of the mammary gland is 
heterogeneous and dynamic as the function of epithelial cells evolves throughout a 
woman’s lifetime (Tornillo and Smalley, 2015). This is reflected by the expression of 
different molecular receptors, namely estrogen receptor (ER), progesterone receptors 
(PR) and human epidermal growth factor receptor 2 (HER2), that enable cells to be 
stimulated by different hormones and growth factors.  
In breast tumours, the expression of the above receptors and Ki-67 – a marker of 
proliferation – at the protein level is mostly measured with antibody-based methods. 
Based on these markers, BCs are classified in four main molecular subtypes (Koboldt 
et al., 2012): luminal A (ER[+] and/or PR[+], HER-2[-], low Ki-67), luminal B 
(ER[+] and/or PR[+], HER-2[+/-], high Ki-67), HER2-enriched (ER[-], PR[-], HER-
2[+]) and basal-like (ER[-], PR[-], HER-2[-]). More than 70% of BCs are detected 
with high levels of ER making luminal subtypes the most frequent BC subtype 
(Koboldt et al., 2012). In contrast, up to 50% of normal epithelial cells can express 
ER with only a minority expresses ER at systematically high levels which suggests 
that BC is more prone to develop from cells expressing ER (Cagnet et al., 2018; 
Fridriksdottir et al., 2015). Therefore a large body of the breast cancer scientific 
community has been putting their efforts into elucidating the molecular mechanisms 
of ER signalling ever since the identification of the protein in the late 1950s (Jensen, 
1962). 
INTRODUCTION 
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Figure 2. Schematic representation of the adult mammary gland and its main cellular 
subtypes. Schematic depiction of potential regulatory cross-talk between different ductal 
mammary cells in response to steroid hormone stimulation. Steroid hormones (red circles in 
lumen) activate ER+ epithelial cells (either mature cells or progenitors). BCs are classified in 
molecular and histopathologic subtypes. (Adapted from Visvader and Stingl, 2014) 
 
3. Therapy and endocrine resistance of hormonal cancers 
Because the proliferation of ER-expressing tumour cells is estrogen-dependent, a 
common approach to treat ER-positive BC is to target ER signalling. In this scope, 
two main drug strategies were implemented: a) to inhibit ER protein itself and b) to 
reduce the levels of estradiol, therefore reducing ER activity. The first performing 
antiestrogenic drug, tamoxifen, was developed already in the late 1960s and was later 
followed by ICI 182,780 (aka fulvestrant), both of which are still widely used in 
premenopausal BC patients (Cole et al., 1971; Thompson et al., 1989). In the same 
period, the first aromatase inhibitors (AIs) appeared as researchers started seeking for 
drugs that inhibit aromatases, the enzymes that metabolise androgens into estrogens 
(Brodie and Longcope, 1980). These treatments can be used sequentially or combined 
with other drugs but also with removal surgery of the BC tumour or ovaries where 
estrogens are produced. 
Unfortunately, regardless of treatment type, overall survival is relatively low as 
almost 50% of patients present ultimately an intrinsic (from the first treatment) or an 
acquired (after secondary treatments) endocrine resistance to therapy (Clarke et al., 
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2015). The causes of endocrine resistance are still unclear although many ER-
mediated mechanisms have been suggested. The loss of ER expression in the tumour 
was proposed to be among potential mechanisms but this event is observed in only 
about 10% of patients (Ellis et al., 2008). As a matter of fact, ER has an extended 
network of cofactors with which it cooperates meaning that even if drugs target ER, a 
large number of other cofactors may be affected in more or less predictable ways. 
Therefore identifying ER cofactors and understanding ER signalling is crucial to the 
understanding of endocrine resistance and to the improvement of BC patient outcome. 
4. Estrogen receptor 
ERα and ERβ are members of the nuclear receptor (NR) super-family which contains 
48 proteins that act both as transcription factors and as ligand receptors (Germain et 
al., 2006). In this work, only ERα will be considered, that is the most widely 
expressed form and which we will be referred to as ER for the sake of simplicity. 
When dimerised, ER forms a DNA-binding domain that enables to bind directly to 
DNA, and a ligand-binding domain that binds a large panel of molecules, usually with 
steroid-like structure (Heldring et al., 2007; Schwabe et al., 1993). 17β-estradiol (E2) 
is the most potent female estrogenic hormone whose production starts in the ovaries 
during puberty with hormone level fluctuation from that point due to menstrual cycles 
until menopause, when E2 levels drop (Kuiper et al., 1997). ER comprises also two 
other main domains, AF-1 and AF-2 (that stand for “activation function”) through 
which ER interacts with other TFs as well as receives post-translational 
modifications.  
ER has also been described to have a ligand-independent activity that is rather 
associated with developmental functions (Caizzi et al., 2014). Nevertheless, most of 
ER’s activity is ligand mediated and occurs in the nucleus where ER can bind to a 
multitude of cofactors and regulate gene expression (Figure 3). Until the late 90s, ER 
was studied mostly in the context of promoters and of direct DNA-binding to its 
canonical binding motif known as Estrogen Responsive Element (ERE, 5′-
GGTCAnnnTGACC-3′) (Driscoll et al., 1998). Like for many other TFs and NRs, the 
emergence of genome-wide sequencing technologies opened the access to the entire 
ER binding landscape and revealed that ER binds in majority to cis-regulatory 
elements away from promoters, also known as enhancers (Carroll et al., 2006). 
INTRODUCTION 
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Figure 3. Model depicting the main molecular mechanisms through which ER can regulate 
gene expression and cell signalling. (From Heldring et al., 2007) 
i. ER cistrome 
The term cistrome was first introduced by Lupien et al. in 2008 and was defined as 
the “repertoire” alias the ensemble of binding sites of a transcription factor (TF)
(Lupien et al., 2008). This term is derived from the composition of “cis”, a Latin
prefix already used in chemistry and meaning “on the same side”, and the suffix “-
ome” that initially comes from Greek (-ωμα) and refers to the sum of elements 
defined by the first compound of the term. The term sounds particularly familiar as it 
was inspired by the notorious word “genome” and all its derivatives. In the particular 
case of ER, the cistrome defines the totality of ER’s binding sites which by extension 
intersects importantly the cistrome of ER cofactors. Indeed, through its association 
with other cofactors, ER can regulate a number of genes without directly binding on 
DNA. This way of binding is commonly referred to as “tethered” (Figure 3). 
ii. Transcription factors 
ER can regulate gene expression positively or negatively through its association with 
different types of cofactors. The use of protein identification methods (mass 
spectrometry) and genome binding occupancy assays (ChIP-seq) brought to light new 
ER cofactors such as FOXA1, GATA3 or GRHL2 to the already known AP-1 or 
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AP2γ (McPherson and Weigel, 1999; Mohammed et al., 2013; Theodorou et al., 
2013). In cell differentiation models, FOXA1 was the first TF to be termed a 
“pioneer” factor because it was detected as the chronologically first factor to access 
closed regions of chromatin (Boller et al., 2016; Cirillo et al., 2002). FOXA1 has been 
extensively studied in the context of ER signalling where it was shown to occupy 
more than half of ER binding sites (Hurtado et al., 2011). Subsequently, it was shown 
that FOXA1 resides stably on DNA in time and this regardless of E2-activated ER 
which suggests that FOXA1 is already settled in chromatin in the context of 
differentiated BC cells in comparison to developmental models (Glont et al., 2019; 
Swinstead et al., 2016). Furthermore, DNA binding motif search revealed that 
FOXA1 as well as GATA3 motifs occur at regular distances of <100bp from ER 
binding sites, suggesting that the three TFs co-bind in close proximity (Serandour et 
al., 2013). GATA3 is a TF that also plays a prominent role in ER signalling as it was 
found to form complexes with ER and FOXA1. Interestingly, up to 16% and 18% of 
breast invasive carcinomas harbour mutations or copy number alterations in GATA3 
and GRHL2, another ER cofactor, against only 6% in FOXA1 and 3% in ER genes 
(Ciriello et al., 2015; Jozwik et al., 2016)2. The number of possible genetic alterations 
is at least as large as the number of ER cofactors which makes breast oncogenesis 
particularly complex to study.  
Similar to ER, the genes encoding the components of the AP-1 complex, the 
transcription factor extensively studied in the context of ER signalling and endocrine 
resistance, rarely carry genetic alterations. AP-1 complex is a heterodimer composed 
of Fos (FOS, FOSB, FOSL1, FOSL2), Jun (JUN, JUNB, JUND), Maf and ATF 
subfamilies and can bind to ER through its AF domains (Kushner et al., 2000). AP-1 
was also described as a pioneer factor in the context of glucorticoid receptor (GR) 
binding in a mouse cell line model (Biddie et al., 2011). AP-1 binds mainly genomic 
regions away from promoters and is a prerequisite to more than half of GR binding 
sites. In BC models, it was shown that anti-estrogenic treatments can generate AP-1 
binding sites that do not rely on ER binding to DNA (He et al., 2018; Webb et al., 
1999). In addition to ER/AP-1 interaction, JNK proteins that phosphorylate and 
activate AP-1 have been shown to be up-regulated in endocrine resistance (Malorni et 
                                                
2  Percentages of mutations and copy number alterations were summed from 
http://www.cbioportal.org data on 817 tumours. 
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al., 2016), leading to the proposal that AP-1 can act independently from ER and 
contribute to endocrine resistance mechanisms. 
5. Chromatin and epigenetic marks 
Regulation of gene expression is the result of a complex molecular gearing where 
TFs, epigenetic regulatory factors (ERFs) and epigenetic marks work tightly together 
on chromatin. Chromatin can be compared to magical yarn where about 2 meters of 
DNA are compacted in tiny balls to fit a cell nucleus and where TFs and RNA 
polymerase II (RNApolII) can access many parts without creating knots or 
unravelling the remaining part. Chromatin evolves dynamically in the short and long-
term and this is achieved thanks to changes in DNA methylation and post-
translational modifications of histones that are commonly referred to as epigenetic 
marks. These dynamic changes are catalysed by ERFs that have either the ability to 
add (“writers”), to remove (“erasers” or “editors”) or simply to recognise (“readers”) 
specific epigenetic patterns on promoters but also on gene bodies and enhancers. 
i. Enhancers 
Besides revealing the entire binding profiles of TFs, genome-wide sequencing also 
revealed a large number of enhancers that are in fact much more numerous than 
promoters (Andersson et al., 2014). Enhancers play the role of docking platforms for 
TFs as well as ERFs and enable chromatin to create loops and consequently to bring 
in spatial proximity regions that are otherwise far in chromosome. While the 
identification of individual promoters and enhancers can be done with histone and TF 
binding assays (ChIP-seq), the construction of promoter-enhancer interaction 
networks requires chromatin conformation assays (Hi-C) (Lieberman-Aiden et al., 
2009). This is also the case for ER where association with a variety of cofactors 
allows establishing chromatin interactions both in proximal and distant cis-regulatory 
elements, mediating concerted gene expression in response to hormonal stimulation 
(Le Dily et al., 2018; Fullwood et al., 2009; Hsu et al., 2010; Rafique et al., 2015). 
While the location of promoters is easily defined by their proximity to the 
transcription start site (TSS), enhancers can operate from hundreds of thousands of 
kilobases away, therefore distance cannot be used as a criterion. In addition, multiple 
enhancers can regulate a given gene and enhancers are cell-type specific which 
further complicates enhancer identification (Heinz et al., 2015; Ko et al., 2017). The 
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location of enhancers is traditionally predicted by the presence of H3K4me1 as well 
as DNaseI and TF footprints, while enhancer activity is defined through p300 binding, 
H3K27 acetylation and enhancer RNA (eRNA) transcription (Charlet et al., 2016; 
Franco et al., 2017; Zhu et al., 2013). Recently DNA methylation hyper-variability in 
relatively small genomic regions have been proposed to predict enhancer activity with 
high efficiency and fidelity (Libertini et al., 2018). 
ii. DNA methylation 
DNA methylation (DNAm) is the covalent addition of a methyl group (-CH3) on the 
5th carbon of a cytosine (5mC) basis that occurs predominantly in the context of a 
CpG sequence in mammalian cells (Smith and Meissner, 2013). In most cases, 
DNAm is symmetric which means that a given CpG in an individual cell can be either 
methylated or unmethylated on either strands. Nevertheless, DNAm is measured most 
of the time in groups of cells that do not necessarily all have the same methylation 
status at a specific CpG. For this reason, DNAm – that is expressed as the percentage 
or the proportion (aka β-value) of the number of methylated sites over the total 
number of CpG sites – can take any value between 0 and 100% or 0 and 1.  
DNAm is edited by two main protein families: DNA methyltransferase (DNMTs) that 
transfer a methyl group from a donor S-adenosyl methionine onto the cytosine, and 
Tet methylcytosine dioxygenases (TETs) that contribute to DNA demethylation 
through a series of oxidation steps (Denis et al., 2011; Ecsedi et al., 2018). In total 
four DNMTs are known in mammalian cells: DNMT1 ensuring the maintenance of 
DNAm during cell cycle, DNMT3a and 3B that deposit DNAm de novo, and 
DNMT3L that has no catalytic domain. DNMTs are often found in the polycomb 
repressive complexes (PRC) which is in line with their role in repression of gene 
expression (Jin et al., 2009). Less is known about TETs since they were discovered 
more recently but more and more evidence show they play a significant role in 
chromatin regulation. The three members TET1, TET2 and TET3 can all catalyse 
5mC into derivative forms, namely 5-hydroxymethylcytosine (5hmC), 5-
carboxylcytosine and 5-formylcytosine, all of which have different chemical 
properties and therefore can affect chromatin states and TF binding at different 
degrees.  
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DNAm has been studied mainly in the context of CpG-dense regions, known as CpG 
islands (CGI), that frequently coincide with gene promoters (Saxonov et al., 2006). 
The current widely accepted view is that DNAm in CGIs is negatively correlated to 
gene expression, meaning that high DNAm levels in promoter are correlated with low 
expression and vice versa. But DNAm occurs also in other genomic contexts and in 
CpG-sparse sequences (namely shores, shelves and open sea regions) where it may 
affect gene regulation in indirect ways. Fore instance, gene-body DNAm, in 
association to H3K36me3, is believed to prevent RNA polymerase II from binding to 
DNA, thereby limiting spurious transcription (Neri et al., 2017) while DNAm in 1st 
intron is inversely correlated to gene expression (Anastasiadi et al., 2018). An inverse 
correlation is also observed in alternative splicing mechanisms where low DNAm of 
introns is linked to higher frequency of intron inclusion at the mRNA transcription 
level (Kim et al., 2018; Shayevitch et al., 2018).  
DNAm levels can be stratified in unmethylated regions (UMRs, β-value <0.1), in 
lowly methylated regions (LMRs, 0.1< β-value <0.5), in partially methylated regions 
(PMRs, 0.5< β-value <0.85) and in fully methylated regions (FMRs, β-value >0.85), 
(Nothjunge et al., 2017; Stadler et al., 2011). Low to intermediate levels of DNAm in 
CpG-scarce regions have been studied in several different contexts, but globally they 
have been associated to dynamic chromatin regions and to TF binding (Sharifi-Zarchi 
et al., 2017). The methylation status of TF binding motifs that contain CpG site can 
affect the TF’s binding affinity either by attracting or repulsing TF (Klose and Bird, 
2006; Yin et al., 2017). Inversely, TF binding itself can also passively preserve 
existing DNAm levels simply by blocking the access to DNMTs (Hervouet et al., 
2018; Lienert et al., 2011). Nevertheless, changes in DNAm alone cannot explain TF 
binding at all sites in vivo (Maurano et al., 2015), which indicates that the importance 
of DNAm likely depends on other factors as well, such as post-translational 
modifications of TFs and histones.  
iii. Histone modifications 
Nucleosomes are spherical octamers of histones (twice of each H3, H4, H2A and 
H2B) that are positively charged and enable the negatively charged DNA to coil 
around them, thereby allowing DNA compaction in the nucleus. Many residues in the 
N- and C-terminal tails of histones are subjected to post-translational modifications 
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(PTMs) that play a crucial role in condensing and loosening up chromatin (Vanzan et 
al., 2017). Furthermore, nucleosomes directly obstruct the access to RNApolII and 
need to be evicted or reorganized during transcription initiation and elongation 
(Workman and Kingston, 1998).  
There are currently hundreds of possible PTMs of histone tails (including covalent 
addition of methyl, acetyl, citrullin and other moieties). Among the most studied 
PTMs are H3K4me1, H3K4me3, H3K27ac and H3K27me3. 
H3K4me1 and H3K4me3 
Several histone methyltransferases (HMTs, such as SET1A, SET1B and MLL1 to 
MLL4) exist that can transfer up to three methyl groups from S-adenosyl methionine 
donors onto lysine and arginine residues of H3 and H4 tails (Clarke, 1993). 
Trimethylation of H3K4 (H3K4me3) by MLL1/2-containing complexes is strongly 
associated to promoters and is necessary for their activation (Wang et al., 2009). The 
addition of one methyl group (H3K4me1) is mostly catalysed by MLL3 and MLL4 
and their presence is associated to enhancers (Yan et al., 2017). In ER-expressing 
cells H3K4me1 deposition at enhancers largely depends on FOXA1 binding and is 
necessary to ER binding at these locations (Jozwik et al., 2016). Both H3K4me1 and 
H3K4me3 usually stretch along large genomic windows, but unlike H3K4me3, 
H3K4me1 is not sufficient to activate an enhancer.  
H3K27ac 
To activate further enhancers and promoters, the 27th lysine residue of H3 needs to be 
acetylated (H3K27ac) (Creyghton et al., 2010). Histone acetylation is mediated by the 
recruitment of histone acetyltransferases (HATs) and more specifically, in 
mammalian cells acetyl is deposited by the catalytic bromodomain of CBP and p300 
(Raisner et al., 2018). H3K27ac marks appear in narrow windows and most of the 
time defining the edges of TF-bound regions. Although H3K4me1 and MLL3/4 are 
not sufficient to activate enhancers, their presence is essential to P300 recruitment 
(Wang et al., 2016). In breast cancer models, ER activation can lead to the 
recruitment of both p300 and AP-1 and highly co-localises with FOXA1 and GATA3 
binding (Jeffy et al., 2005; Murakami et al., 2017; Rosell et al., 2014). Histone 
deacetylases (HDACs) “erase” the acetyl group from histones and consequently lead 
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to a decrease of distance between nucleosomes and ultimately to a condensation of 
chromatin structure (Zentner and Henikoff, 2013).  
Repressive PTMs 
EZH2, that is part of the PRC2 complex along with SUZ12 and EED, is the only 
histone methyltransferase known to methylate H3K27me3 (Comet et al., 2016). It can 
be found on promoters and enhancers and is not mutually exclusive to H3K27ac. 
PRC2 is a large complex that may also contain HDACs and DNMTs and can 
therefore lead to an important gene expression down-regulation (Hernández-Muñoz et 
al., 2005; Marchesi and Bagella, 2016). H3K9me3 is another repressive mark that is 
partially redundant to H3K27me3 since they are often superimposed.  Both H3K9me3 
and H3K27me3 can be read by heterochromatin protein 1 (HP1), a protein that plays a 
role in the constitution of heterochromatin (Jamieson et al., 2016; van de Werken et 
al., 2014). 
iv. Chromatin states 
Dynamic chromatin states are needed to establish tissue- and temporal-specific 
transcriptional programs in response to environmental and endogenous stimuli. 
Initially, chromatin was approximately distinguished into euchromatic and 
heterochromatic domains based on the intensity of staining observed in microscopy 
(Elgin, 1996). Ever since, the integration of genome-wide epigenetic, transcription 
and chromatin-conformation data has revealed a complex and multilayer regulation of 
chromatin. 
Conventionally, DNAm is associated to heterochromatin. Nevertheless, intermediate 
DNAm is both positively and negatively correlated to H3K27ac at enhancers when 
considered in large genomic bins (Charlet et al., 2016). This lack of correlation could 
be accounted to intermediate DNAm levels, which include a large spectrum of DNAm 
levels (LMRs + PMRs). DNA methylation levels should also be considered at the 
single CpG level rather than in regions, especially in the context of enhancers. For 
instance, hypomethylation has been associated with large nucleosome-depleted 
regions (NDRs) while punctual methylation of histone-bound fraction of DNA seems 
to contribute to a more open structure (Jimenez-Useche et al., 2013; Taberlay et al., 
2014).  
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The cross-talk between DNAm and histone marks is believed to be mediated by 
complexes that contain ERFs that are sensitive to DNA and/or histone methylation. 
For instance, MLL1/2, that deposit H3K4me3, contains a zinc finger CXXC domain 
that has high affinity for unmethylated DNA and is often found on promoters (Birke 
et al., 2002; Wang et al., 2009). Inversely, MLL3/4 lack the CXXC domain and this 
can be reflected by the heterogeneous levels of DNAm found at enhancers (van 
Nuland et al., 2013; Sze and Shilatifard, 2016). CTCF, that contributes to the 
definition of topologically associated domains (TADs) and to insulation mechanisms, 
was believed for a long time to be mutually exclusive to DNAm but recent integration 
of 5hmC data shows that the affinity of CTCF binding is more subtle than initially 
thought (Dixon et al., 2012; Wiehle et al., 2019).  
The global picture of chromatin dynamics proves to be highly complex, especially 
regarding the role of DNAm. Nevertheless, DNAm, histone marks and TF binding in 
specific genomic contexts can be combined to define four chromatin states (Caglio et 
al., 2017; Calo and Wysocka, 2013) applicable to both promoters and enhancers but 
are more described in the context of the latter (Figure 4): 
• Active enhancers carrying H3K4me1 as well as H3K27ac marks and 
exhibiting binding of MLL3/4 and p300 as well as producing eRNA. 
• Primed enhancers maintaining H3K4me1 and showing lower, albeit not null, 
levels of H3K27ac, MLL3/4 and p300 and do not produce eRNA. 
• Poised enhancers are similar to primed but in addition carry the repressive 
mark H3K27me3. 
• Repressed enhancers showing no methylation on H3K4 and having high 
levels of H3K27me3 and/or H3K9me3. 
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Figure 4. A simplified summary of histone modifications and DNAm used as traditional 
predictors of chromatin states. Methylated and unmethylated CpG sites are represented as full 
or empty lollipop-circles. 
6. ER, DNA methylation and breast cancer 
BC, similar to a vast majority of cancers, can occur following epigenetic alterations 
and is characterised by a global hypomethylation and a focal hypermethylation 
(Feinberg and Vogelstein, 1983; Herceg and Hainaut, 2007; Szyf et al., 2004). The 
fruition of large-scale sequencing efforts, spearheaded by The Cancer Genome Atlas 
(TCGA), and the Encyclopedia of DNA Elements (ENCODE) project has 
substantially accelerated our understanding of cancer (epi)genome. By matching high 
throughput data from hundreds of human tumour and normal (non-tumour) samples 
with similar data from cell line models, researchers have been gradually bridging the 
gap between clinical and basic research. For BC, the differences in methylome were
shown to be largely driven by the expression of hormonal receptors that are used to 
define the classical molecular subtypes of BC (Fernandez-Jimenez et al., 2017; Holm 
et al., 2010). For instance, the basal-like (triple-negative) subtype was shown to be the 
most hypomethylated BC subtype (Koboldt et al., 2012), although the underlying 
mechanism remain unknown.  
In 2014, Ung et al. overlapped ER binding sites from ER-positive cell line MCF-7 
with BC methylome data (Illumina Infinium HumanMethylation450 BeadChip) from
TCGA and found that while ER-positive cancers were globally hypermethylated in 
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comparison to ER-negative subtypes, DNAm at ER binding sites was substantially 
lower in ER-positive tumours (Ung et al., 2014). A similar observation was 
subsequently reported for DNAm at FOXA1 binding sites that was found 
considerably lower in tumours expressing both FOXA1 and ESR1 (Ciriello et al., 
2015). This is strongly in line with in vitro results showing that knock-down of 
FOXA1 in MCF-7 cells leads to an increased methylation on CpGs included within 
±500bp away from FOXA1 peaks (Zhang et al., 2016). Interestingly, it was earlier 
suggested in a different cell line model that FOXA1 actually triggers an active DNA 
demethylation (Sérandour et al., 2011). Binding of ER, FOXA1, GATA3 and FOS 
was found significantly enriched at functional enhancers that had lower DNAm levels 
in ER-positive compared to ER-negative BC (Fleischer et al., 2017). This raises the 
possibility that the specific mechanisms are conserved between cell line models and 
clinical samples. Finally, long term E2 deprivation in MCF-7 was also shown to lead 
to a global hypermethylation, a small portion of which overlapped with ER-bound 
enhancers, based on which a mechanism playing a role in endocrine resistance was 
proposed (Stone et al., 2015). Together, these results strongly indicate that ER and its 
cofactors may play a role into the maintenance of lower DNAm levels at enhancers. 
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7. Hypothesis and aims
Based on the current knowledge, I hypothesised that ER positively regulates gene 
expression by shaping the chromatin and more specifically by keeping DNA 
methylation low and histone acetylation high at ER binding sites (Figure 5). In the 
presence of E2, ER and its cofactors would occupy DNA and passively maintain these 
epigenetic marks by preventing repressive complexes to access these sites through 
simple steric hindrance. In the absence of E2, the ER-dependent complexes would not 
form permitting repressive complexes containing DNMTs and/or HDACs to change 
epigenetic marks, therefore to switch to repressed chromatin states and to down-
regulate gene-expression. Finally, I also put forward the hypothesis that if ER is re-
activated by its ligand, the changes in epigenetic marks may not be reversible. The 
removal of E2 may mimic the mechanism of aromatase inhibition and therefore this 
project could to contribute to disentangling further the mechanisms underlying 
endocrine resistance. 
The specific aims are: 
• To show that modulating estradiol-mediated ER activity has an impact on 
genome-wide DNAm and histone acetylation. 
• To address the functional impact of these epigenetic changes. 
• To assess the reversibility of these epigenetic changes. 
Figure 5. Mechanistic hypothesis of the maintenance of epigenetic marks and gene regulation
in relation to E2-dependent ER activity. 
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MATERIAL AND METHODS 
1. Cell culture and treatments 
i. Rationale behind a new stricto sensu E2-dependent cell culture protocol  
In order to model the effect of steroid hormones in cell culture, many previous studies 
used the E2-deprivation/re-stimulation approach (Ryan et al., 2016). Briefly, an ER-
positive cell line, typically MCF-7, is deprived for several days from E2 after which 
the cells are re-stimulated with E2 and the endpoint of interest is measured. This 
system allows exploring two distinct phenomena: 1) the effect of E2 removal from the 
medium, alias deprivation and 2) the effect E2 re-introduction, alias re-stimulation, 
both of which are mediated by ER. Nevertheless, if one aims to study the potential 
reversibility of epigenetic changes resulting from E2 deprivation subsequently 
followed by E2 re-stimulation the existing protocols present certain limitations. In the 
following section, I address some of these limitations, and I present a methodological 
approach that circumvent these shortcomings. 
The very extensive use of E2 deprivation/re-stimulation protocol has the consequence 
of increasing number of parameters that vary within and between laboratories. The 
origin of the MCF-7 cell line, the composition of growth medium, the quality of 
charcoal stripping of serum, the duration of E2-deprivation or the E2 concentration 
used for re-stimulation, are some examples that can affect the estrogenic growth dose-
response and hence contribute to reproducibility issues (Kleensang et al., 2016; Sikora 
et al., 2016). Firstly, it is important to know that although there are multiple cell 
culture alternatives, the main E2 deprivation protocol consists into passing ER-
positive cells from medium containing standard serum to medium containing 
charcoal-stripped serum (CSS). Charcoal stripping is a chemical process that removes 
lipophilic compounds such as steroid hormones (E2, progestogens, androgens), 
several growth factors and some cytokines. E2 re-stimulation is subsequently 
performed by adding E2 on previously deprived cells. This method has been applied 
in a multitude of studies, some of which have focused on the effect of long-term E2 
deprivation in MCF-7 on multiple readouts with the aim to characterise the 
mechanisms of endocrine resistance (Aguilar et al., 2010; Jeng et al., 1998; Santen et 
al., 2008; Stone et al., 2015). Long-term deprivation mimics the decrease of E2 blood 
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levels that occurs in women with hormono-dependent breast cancer that either 
underwent oophorectomy or were treated with aromatase inhibitors (Santen et al., 
2008). In vitro, the protocol of long-term E2-deprivation (LTED) consists into 
culturing MCF-7 in medium containing CSS for durations ranging from 4 to 24 
months and to compare the readout to that of MCF-7 maintained in regular-serum 
medium. This protocol design is problematic, given that the control group is cultured 
in medium containing regular serum containing all components previously mentioned. 
This means that the comparison of the outputs does not reveal effects of E2 
deprivation alone, but cumulates indistinguishably the effect of other steroid 
hormones and growth factors that affect MCF-7 cell processes (Azeez et al., 2015; 
Macedo et al., 2006). Although the removal of E2 could be the main cause of the 
observed changes, it is not possible to exclude that the final LTED phenotype is the 
result of synergistic deprivation. This observation is of minor impact in the context of 
studies using short E2 deprivation – usually 3 days alias one passage – that are mostly 
aimed at elucidating ER dynamics at a mechanistic level. 
In addition to the above limitation, one has to consider the capacity of cancer cell 
lines, in spontaneously evolving into different subclones (Hara et al., 1993; Qu et al., 
2015). Particularly MCF-7 is known to be a heterogeneous cell line that contains 
endocrine resistant subpopulations (Devarajan et al., 2002; Kleensang et al., 2016).  
These endocrine resistant clones often lose their dependence to ER and do not 
respond to E2 modulation. To avoid the issue of spontaneous specification, it has been 
suggested to perform assays within less than 20 to 25 cell passages (Nelson, 2016). 
Keeping in mind the considerations described above, the main concerns for designing 
the experiments were:  
1. Focusing strictly on the effect of E2 deprivation and not the effect of charcoal 
stripped serum 
2. Having a control that can be commonly compared to both E2 deprived and E2 
re-stimulated condition to study the putative reversibility of the effects due to 
deprivation 
3. Culturing cells long enough to obtain observable effects, but not too long to 
avoid loss of estrogen response 
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In order to respect the above constraints and since removing E2 alone from CSS is not 
chemically possible, I opted for an inversed approach: to deprive cells from all 
components with the use of CSS and to maintain only E2 (and its solvent) in the 
medium by adding it on a regularly basis. To implement this, as soon as MCF-7 cells 
were thawed, they were placed in culture in phenol-red-free medium (another weak
ER agonist) supplemented with CSS as well as a daily input of E2. They were 
maintained and subcultured in this medium until the beginning of the experiments,
which usually took approximately 2 weeks and 4 passages. In this way, I made the 
assumption that by the beginning of the experiments, most changes resulting from the 
absence of charcoal-stripped components would be evened out, or at least minimised. 
To specifically address the deprivation of E2 stricto sensu, MCF-7 were cultured in 
parallel in two groups; a control group (CTR) cultured in the above mentioned 
medium with E2, and a E2-deprived group (E2D), cultured in the same conditions, 
only lacking E2 (Figure 6). As for assessing the reversibility of the effects deriving 
from the deprivation, a third group of cells was simply re-stimulated with E2 (ReSt) 
after being deprived from it for a certain period. The presence of E2 being the only 
difference between CTR, E2D and ReSt groups, the comparison of all groups
becomes possible and we can study mechanisms that are strictly ER-mediated. 
Figure 6. Experimental design for the study of E2 deprivation and re-stimulation 
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Concerning the duration of the treatment, we know from experience that changes in 
expression can be measured in a matter of hours while there is less evidence about the 
time needed for DNAm changes to be detectable. As a starting point, I followed the 
most employed duration of E2 deprivation that is used for mRNA expression 
measuring, that is 3 days of deprivation (Stanislawska-sachadyn et al., 2016). For the 
E2 re-stimulation, the durations in literature vary from 30 minutes to 48h and I chose
24h. With these conditions, we ran a pilot 850k array (see Material & Methods 
section later). 
For the sake of readability, the details of the pilot analysis will not be shown but 
briefly, no significant differences in DNA methylation were found using the canonical 
linear regression model that is used in the context of methylation array analysis
(Aryee et al., 2014). Nevertheless, with the use of the more sensitive beta regression
(Ferrari and Cribari-Neto, 2004), 1885 DMPs  were detected of which only 3% had 
differential methylation >10% after 3 days of E2 deprivation. The beta regression 
though proven to be also less specific as only 6 out of 10 tested DMPs were 
technically validated. Based on this pilot assay, I concluded that more samples would 
increase slightly the robustness of statistics but especially that a longer E2 deprivation
and re-stimulation would increase the amplitude of DNA methylation changes.
Therefore, I increased the total duration of the assay to 14 days and the E2 re-
stimulation particularly lasted for 10 days after 4 days of deprivation (Figure 7). All 
further experiments were based on this core design. 
Figure 7. Experimental design for the study of E2 deprivation and re-stimulation 
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In summary, the optimisation of the E2 deprivation and re-stimulation protocol offers: 
• A good compromise to study both E2 deprivation and re-stimulation in 
relation to each other and in one single assay  
• A strict approach enabling the study of a single molecule. 
ii. E2 deprivation and re-stimulation of MCF-7 
MCF-7 HTB-22® cells were obtained from the American Type Culture Collection 
and all assays in this thesis were performed within 12 passages. Fresh E2 stock 
solutions at 1µM in 100% DMSO were regularly prepared, they were stored at -20°C 
in aliquots <50µL and were single-used daily to ensure a continuous availability of E2 
in the medium. MCF-7 cultured for the E2 deprivation/re-stimulation and the siRNA 
assays were expanded for two weeks in phenol-red-free DMEM/F-12 supplemented 
with 10% (v/v) charcoal-stripped fetal bovine serum (csFBS, Sigma-Aldrich), 1% 
nonessential amino acids, sodium pyruvate and penicillin/streptomycin (Life 
Technologies) and with a daily addition of 10nM E2 and 0.1% DMSO (Sigma-
Aldrich) at 37°C, in a humidified and 5% CO2-enriched atmosphere (E2+CSS 
medium). For the assay itself, control cells (CTR) were cultured continuously for 14 
days in the above-mentioned conditions, while E2-deprived cells (E2D) were cultured 
in the same conditions only lacking E2. The re-stimulated cells (ReSt) were deprived 
from E2 for 4 days and re-stimulated for the 10 following. Cells were cultured in 
triplicates and collected at day 0, 4 and 14 for downstream analysis.  
iii. ER inhibition and re-activation by antagonists 
Another way to validate the effect of sequential ER inactivation and re-activation, is 
to apply and later remove ER inhibitors from the culture conditions. In order to keep 
ER deprivation and ER inhibition protocols comparable, I wanted initially to keep the 
same basic medium composition (phenol-red-free medium, CSS and E2) and add the 
ER antagonist in higher concentration to E2. To test if cells were responsive to these 
inhibitors, MCF-7 were exposed for 4 days to two well known antagonists separately 
at 1µM, fulvestrant or ICI 182,780 (ICI), a selective estrogen receptor degrader 
(SERD), and (Z)-4-hydroxytamoxifen (shortly tamoxifen, TAM), a selective estrogen 
receptor modulator (SERM) (Cole et al., 1971; Wakeling et al., 1991). During this 
exposure, the drugs were renewed twice, along with E2. For both drugs, expression of 
ER downstream targets is expected to change. After 4 days, I measured the expression 
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levels of GREB1, a gene positively regulated by ER, as a proxy of ER activity (see 
Material & Methods section later). Surprisingly, I discovered that under the E2+CSS 
culture conditions, the expression of GREB1 remained unchanged (Figure 8A). After 
several tests changing concentrations of components, I abandoned the idea of 
culturing cells in E2+CSS medium and I switched to using medium containing regular 
FBS. Interestingly, this led in the expected result, meaning the down-regulation of ER 
target GREB1 in both ICI and TAM treatments (Figure 8B).  
Figure 8. Expression of ESR1 and ER target gene GREB1 in response to 1µM of ICI 182,780
(ICI) and 1µM of tamoxifen (TAM) after 5 days of treatment. (A) MCF-7 were cultured in 
phenol-re-free medium, CSS and 10nM of E2 (CTR) in addition to an antagonist. (B) MCF-7 
were cultured in standard medium and FBS in addition to an ER antagonist. Results are 
shown as the average expression of triplicates ± SD. 
I therefore performed downstream inhibition assays using medium containing regular 
FBS as follows. MCF-7 meant for exposure to the inhibitors were maintained for two 
weeks in DMEM supplemented with 10% fetal bovine serum (Eurobio), 1% 
nonessential amino acids, sodium pyruvate, penicillin/streptomycin and 0.1% DMSO. 
The control cells (CTR) were cultured in the condition above, inhibited cells (ICI) 
were cultured in continuous presence of 1µM ICI and re-activated cells (ReAc) were 
cultured in presence of the inhibitor for 4 days followed by control conditions for 
another 10 days (Figure 9). Cells were cultured in triplicates and collected at day 0, 4 
and 14 for downstream analysis.
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Figure 9. Experimental design for the study of ICI 182,780 (ICI) inhibition and re-activation. 
 
iv. ER down-regulation by siRNA 
MCF-7 were cultured until the beginning of the siRNA transfection as mentioned in 
section 1.ii of Material and Methods. Cells were transfected as recommended by the 
manufacturer’s reverse transfection protocol (Invitrogen). In detail, MCF-7 were 
transfected with 10 nM of siRNA pool against ESR1 or 10 nM of non-targeting 
siRNA (Dharmacon, On-Target Plus siRNA) using 2.5µL of RNAiMAX 
lipofectamine for a 6-well format (Life Technologies). Cells were maintained in the 
transfection mix during 48h and were harvested 72h later, which corresponds to a 
total of 5 days from the day of transfection. RNA and DNA where extracted as 
described in the equivalent section. Expression of ESR1 and GREB1, a direct target of 
ER, was measured to verify the efficiency of silencing. The percentage of knock-
down was calculated as the ratio of the average relative expression of ESR1 in 
siESR1 over siNT treated cells. 
2. Molecular biology 
i. DNA and RNA extraction 
For all assays involving DNA and RNA, total DNA and RNA were extracted using 
AllPrep DNA/RNA Mini kit (Qiagen). DNA was quantified by Qubit dsDNA HS kit 
(Invitrogen) while quality and quantities of RNA were assessed on a ND-8000 
spectrophotometer (Nanodrop). Eluted DNA was stored at -20°C and RNA at -80°C 
until further use. 
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ii. Bisulfite conversion 
In this work, DNA was used for the only purpose of measuring CpG methylation. To 
quantify the percentage of methylated cytosines, we used bisulfite conversion that 
causes unmethylated cytosines to be converted into uracil bases while methylated 
cytosines remain as such (Vaissière et al., 2009). For samples processed on the 
Infinium MethylationEPIC array (Illumina), 600 ng of DNA were converted with the 
EZ DNA Methylation kit (Zymo Research) 250 ng of which were used for the 
hybridisation. Samples processed by pyrosequencing were converted with a EZ DNA 
Methylation Gold kit (Zymo Research). In both cases DNA was eluted in 20 µL and 
stored at -20°C until further use. 
iii. Pyrosequencing 
Pyrosequencing was performed as previously established in our team (Vaissière et al., 
2009).10 to 25 ng of modified DNA was amplified by PCR in a final volume of 50 
μL. 8 μL of PCR reaction was analysed on a 2% agarose gel to confirm efficacy of the 
reaction. The remaining volume of modified DNA was used for the pyrosequencing 
assay itself. One of the primers used for each PCR reaction carried a 5’-biotinyl 
modification. Briefly, the PCR amplicons were bound onto streptavidin-coated 
sepharose beads (Amersham-GE Healthcare), which attract the biotinylated strands. 
Pyrosequencing was carried out in accordance with the manufacturer's protocol using 
PyroGold Reagent kit (Qiagen) on the vacuum-based workstation (PSQ 96MA, 
Biotage). The methylation levels of the CpGs of interest were evaluated by converting 
the resulting pyrograms to numerical values based on their peak heights. Primers for 
PCR and sequencing primers are presented in Table 1. 
Table 1. Primer sequences to measure DNA methylation by pyrosequencing. Primers carrying 
a biotine modification at their 5’ contain “BIO” in their name 
Primer Sequence 
Sequencing 
primer Genomic range 
Amplicon 
(bp) 
Annealing 
Temp (°C) 
cg12667152_F 
AGTTATGATGGGGT
GGAGAAA 
Same as 
forward 
chr11:85,884,137-
85,884,246 110 <55.8 
cg12667152_BIO_R 
AAAATCCCTACTAA
TCCACACAAA         
cg10612997_F 
TGTGTTATTGATGA
AGTTTTTGAG 
TTAGGGGAGA
ATATG 
chr2:11,673,902-
11,674,119 218 61 
cg10612997_BIO_R ACTAAAATCTACAC         
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ACCATACTCTCC 
cg03192421_F 
AGGATTGTGAATAT
TATGTTATTGTG 
GTTTATAATGG
TAAT 
chr20:10,643,103-
10,643,295 193 56 
cg03192421_BIO_R 
CAAACCAAAATCAA
CCTCAA         
cg04210444_F 
GTTTGTGTGAATAG
AGGTTTTAGG 
Same as 
forward 
chr20:46,397,276-
46,397,410 135 56 
cg04210444_BIO_R 
CACACTACCTTCTC
TTATCAATTATCA         
cg17407893_BIO_F 
GTGGTATTTGGGAA
TTTGTTG 
GTAATTTGTGT
TTTA 
chr16:16,119,175-
16,119,303 129 61 
cg17407893_R 
CAAAAACCCTCCCA
CTAAATT         
cg13670878_BIO_F 
AGTGGATGGTAAGT
GAGAGG 
TATTTAAAATT
AAC 
chr2:11,681,555-
11,681,896 342 58 
cg13670878_R 
CAACCTAAACCCTA
CTAAAATATTTA         
cg13374172_F 
TATGTTTGAGTTAG
TAAGAGGGG 
Same as 
forward 
chr8:56,860,886-
56,861,092 207 56 
cg13374172_BIO_R 
CCCATACATAATAC
TTAAAATATCACTT         
cg26126617_F 
GGTTTGGATTAAAT
AGAGGAGTATTTG 
Same as 
forward 
chr2:25,077,082-
25,077,220 139 56 
cg26126617_BIO_R 
CCAAAACCCCTAAA
TAATATAACCAC         
 
iv. Chromatin immunopricipatation 
MCF-7 were cultured in duplicates in CTR, E2D and ReSt conditions as mentioned 
above and were formaldehyde-fixed at 1% for 8 minutes. The equivalent of 2 million 
cells were sonicated and processed with the iDeal ChIP-seq kit for histones as per the 
manufacturer’s protocol (Diagenode). Chromatin from 1 million cells was 
immunoprecipitated with 2.5 µg of anti-H3K27ac, anti-H3K4me1 and anti-
H3K27me3 antibodies (ab4729, ab8895, ab6002, Abcam). ChIPed and input DNA 
was extracted using the iPure kit (Diagenode). The same sonication conditions were 
used as for ChIP-seq (see below for details).  
v. mRNA retro-transcription and quantitative RT- and ChIP-PCR 
Reverse transcription reactions were performed using MMLV-RT enzyme 
(Invitrogen) and random hexamers on 500 ng of total RNA per reaction as per the 
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manufacturer’s protocol. Quantitative RT-PCR was done in triplicate for each 
condition. The PCR conditions used were: 95°C 5min, [95°C 15 s, 61°C 30 s] × 40 
cycles, 95°C 1 min. The assays were performed using SYBR Green qPCR mix and a 
CFX96 RealTime PCR Detection System (Bio-Rad Laboratories). Expression levels 
were calculated using the 2-ΔCt method (Livak and Schmittgen, 2001)chip. Results 
from ChIP were calculated as a percentage of input (previously diluted 1:10). The 
primers used for RT and ChIP-qPCR are reported in Table 2 and Table 3 
Table 2. Primer sequences used to measure gene expression 
Primer Sequence Amplicon (bp) Source 
qRT_GREB1_F ATGGGAAATTCTTACGCTGGAC 171 designed in this study 
qRT_GREB1_R CACTCGGCTACCACCTTCT     
qRT_TFF1_F TCGAAACAGCAGCCCTTATT 102 designed in this study 
qRT_TFF1_R GGCCCAGACAGAGACGTGTA     
qRT_PGR_F TTATGGTGTCCTTACCTGTGGG 112 designed in this study 
qRT_PGR_R GCGGATTTTATCAACGATGCAG     
qRT_FOS_F AAGCGGAGACAGACCAACTA 134 designed in this study 
qRT_FOS_R CAGGTCATCAGGGATCTTG     
qRT_JUN_F AACAGGTGGCACAGCTTAAAC 77 PrimerBank ID 44890066c2 
qRT_JUN_R CAACTGCTGCGTTAGCATGAG     
qRT_HDAC9_F AGTAGAGAGGCATCGCAGAGA 141 PrimerBank 116284378c1 
qRT_HDAC9_R GGAGTGTCTTTCGTTGCTGAT     
qRT_PADI4_F CAGGGGACATTGATCCGTGTG 130 PrimerBank 216548486c1 
qRT_PADI4_R GGGAGGCGTTGATGCTGAA     
qRT_MMP13_F ATTTCTCGGAGCCTCTCAGT 103 designed in this study 
qRT_MMP13_R AGTTTGCAGAGCGCTACCT     
qRT_RPLP0_F TGGCAGCATCTACAACCCTGAA 90 designed in this study 
qRT_RPLP0_R ACACTGGCAACATTGCGGACA     
qRT_TNIK_F TAAGGGTCGTCATGTCAAAACG 173 PrimerBank 239735578c1 
qRT_TNIK_R CCATGCCTGGTGGGTTCTTT     
qRT_TET2_F CTTTCCTCCCTGGAGAACAGCTC 146 designed in this study 
qRT_TET2_R TGCTGGGACTGCTGCATGACT     
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Table 3. Primer sequences used to measure histone mark enrichment by qPCR 
Primer Sequence 
Amplicon 
(bp) Source 
Peak1_F GCTTGCAGGCAGAAATGTAAACAC 136 designed in this study 
Peak1_R CTGTTGCCCTAAGCCTGTATT     
Peak2_F GTTGTGTGGACCATATTTTCTAAAC 102 designed in this study 
Peak2_R TGTTTACATTTCTGCCTGCA     
Peak3_F TTAAACAGTTCTCCTCCACTCC 74 designed in this study 
Peak3_R GCAGATTACAAAACTCACTGAAGAC     
Peak4_F TGATGTGTCAGGAACCCTCC 92 designed in this study 
Peak4_R CCCAGACCTACTGCATCAGAAAC     
GREB1_pos_F CACGTCCCCACCTCACTG 56 Jozwik, 2016, Cell Reports 
GREB1_pos_R TGTTCAGCTTCGGGACACC     
SPATA16_neg_F GACGCCAGGACTTGAAAC 102 designed in this study 
SPATA16_neg_R TCAAGTGCAACTCAAGAGGA     
 
3. OMICs and data analysis 
i. Methylation bead arrays 
250 ng of bisulfite converted DNA were hybridised on an Infinium MethylationEPIC 
array, referred to as 850k from this point (Illumina). Processing and normalization of 
data followed by identification of differentially methylated positions (DMPs) was 
performed as described earlier using Bioconductor package minfi (Degli Esposti et al., 
2017; Fortin et al., 2016). Annotation of probes was done with the use of 
IlluminaHumanMethylationEPICanno.ilm10b2.hg19 (Hansen, 2017). To determine 
the effect of E2D deprivation on DNAm, we used a linear regression model (limma) 
where we compared E2D (n=6) treatment to CTR (n=9) while adjusting for timepoint 
and applying a differential methylation cutoff of 10% (false discovery rate, FDR 
<0.05; Δβ ≥10%) (Ritchie et al., 2015). Then, to test the reversibility of this effect, we 
applied a linear regression model between CTR and ReSt samples at d14. Drawing of 
QQ-plots and calculation of lambda (inflation factor) were done as per (Yang et al., 
2011). FDb.InfiniumMethylation.hg19 and ChIPseeker R/Bioconductor packages 
were used for annotating the DMPs (Triche, 2014; Yu et al., 2015). 
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ii. ChIP-sequencing 
The library preparation requires an initial DNA fragment size ranging 200-800bp. 
Because large fragments persisted with the increase of sonication cycles while small 
fragments became further fragmented, I decided to sonicate chromatin 14x (30sec 
ON:OFF, Bioruptor Pico) and to perform a fragment size selection downstream, after 
the ChIP (Figure 10). The very first step of the TruSeq library preparation consists 
into performing a small fragment clean-up using AMPure beads. After various tests, I 
found that a ratio of 0.5x AMPure beads (volume beads:DNA) successfully got rid of 
large-sized fragments (>800bp). I incorporated this extra step at the very beginning of 
library preparation and proceeded as per the manufacturer protocol with 10 ng of 
initial cleaned-up ChIPed DNA. For input, equal amounts from duplicate CTR at d4 
and d14 were pooled to generate the input (1.67µL from each, 10µL in total diluted 
1:10), which was de-cross-linked and further treated like the remaining ChIPed 
samples. 
Figure 10. DNA fragment size distribution after sonication of chromatin for 6 to 16 cycles 
(30sec ON, 30sec OFF Bioruptor Pico) 
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Figure 11. Fragment size distribution of 14x sonicated chromatin, before ChIP (upper panel) 
and after anti-H3K27ac ChIP and 0.5x AMPure bead purification (measured on bioanalyzer). 
In between the red lines is indicated the fragment range that will be finally sequenced (add ± 
120bp for adapters and end-repair) 
 
H3K27ac ChIP and input libraries were prepared using the TruSeq ChIP Sample Prep 
kit and we performed paired-end sequencing with the NextSeq 500/550 High Output 
Kit v2.5 (150 Cycles) (Illumina). Fastq files were trimmed using TrimGalore for 
adapters and a minimum quality of Q >30 (Babraham Bioinformatics3), then mapped 
on hg19 using BWA and further processed as previously described (Jozwik et al., 
2016; Li and Durbin, 2009). Mapped read numbers ranged between 125 and 174 
million, which is higher than the amount of reads recommended by ENCODE. 
Narrow peaks were then called with MACS2 (2.1.1.20160309) against input and were 
filtered ad hoc for <1.5kb width, q <0.01 and fold-change from input >5 (Zhang et al., 
2008). For downstream analysis we worked with irreproducible-discovery-rate (IDR) 
thresholded peaks. Differentially bound (DB) regions were identified with DiffBind 
                                                
3 http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ 
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between different groups at d14 and only DB peaks with |log2FC|  >1 were considered 
(Stark R, 2011). 
iii. RNA-sequencing 
Total RNA was extracted along with DNA using the AllPrep DNA/RNA Mini kit 
(Qiagen). One µg of RNA was used for TruSeq RNA library preparation (Illumina) 
following the manufacturer’s protocol and single-end sequencing was performed on 
HiSeq 4000 yielding at least 20M 50bp-reads for each sample. Following quality 
control, reads were trimmed at 30bp and mapped on hg19 with hisat2 with mapping 
efficiencies of ≥87% (Kim et al., 2015). Read counts were generated from bam files 
using htseq-count function and genes with ≤10 counts-per-million in at least two 
samples were eliminated (Anders et al., 2015). Differentially expressed genes were 
identified between CTR and E2D adjusting for time and between CTR and ReSt at 
d14 using edgeR (FDR <0.05, |log2FC| >1) (Robinson et al., 2010). 
4. Other data analysis 
i. De novo motif analysis 
A de novo TF motif enrichment analysis was performed after enlarging the genomic 
window to 250 bp around DMPs and to 1 kb for DB H3K27ac, using the 
findMotifsGenome.pl function from HOMER v.4.8.3 (Heinz et al., 2010). Whole 
genomic ranges were kept as such for de novo motif search in publically available TF 
ChIP peaks. 
ii. TF and histone enrichment  
The ChEA database, provided online by the EnrichR collection of tools, was used for 
the first evaluation of the enrichment of TF binding on DEGs and genes mapping 
close to DMPs and DB H3K27ac regions (Kuleshov et al., 2016). Only TF 
enrichments with an adjusted p-value <0.05 were considered. For overlaps with 
specific TFs, histone marks and ChromHMM annotations, we downloaded published 
histone and TF ChIP-seq datasets (Table 4) and we overlapped them with the genomic 
ranges of DMPs, DB H3K27ac peaks and DEGs produced in this study. All public 
datasets used were based on MCF-7 cells cultured in E2 containing media. Whenever 
possible, optimally IDR-thresholded peaks mapped on hg19 were downloaded. 
Histone ChIP-seq datasets contained a large amount of peaks, many of which carried 
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a low signal. To be more stringent, we ranked peaks by signal and we filtered out the 
second half of the peaks. E2-specific peaks were derived from ER peaks that were 
present in E2-treated MCF-7 and absent from E2 deprived cells (Swinstead et al., 
2016). The enrichment was calculated as the ratio of genomic-range overlap of the 
differential hits over the overlap with the total probes, peaks or expressed genes 
respectively for each dataset (differential/expected). More precisely, for DNAm we 
used the genomic ranges of all probes on the 850k array, for H3K27ac marks we used 
the IDR-thresholded peaks of CTR at d14 and for transcription we used the genomic 
range of expressed genes. Fisher’s exact test was used to evaluate enrichments with a 
nominal significance level of p<10-5. This approach should be taken with some 
caution in the context of DEGs because the size of genes is variable and very large 
and therefore this particular analysis resulted in large fractions of overlap with mostly 
null fold-enrichments. 
iii. DNAm and transcription correlation 
FDR-significant DMPs and DEGs were correlated within CTR and E2D samples 
(n=12) at with and without any differential cut-off (Δβ ≥10% for DNAm and |log2FC| 
>1 for gene expression), using an FDR-adjusted Spearman correlation. DNAm and 
transcription data were obtained from the same samples. DMPs were matched to the 
closest expressed gene, upstream or downstream. 
iv. Statistics for targeted experiments 
For all targeted experiments (pyrosequencing, RT-qPCR and ChIP-PCR) I performed 
pairwise non-parametric tests, namely Mann-Whitney test. For DNAm data and 
H3K27ac-ChIP, only timepoint d14 was considered (n=3 per group) and for relative 
mRNA expression, both d4 and d14 were considered (n=6 per group). P-values <0.05 
were considered as significant. Statistical comparisons were performed with R version 
3.5.1.  
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Table 4. List of ChIP-seq datasets produced in MCF-7 used in this work. 
 
v. Visualisation 
For the visualization of H3K27ac peaks on IGV (2.4.19) (Thorvaldsdóttir et al., 
2012), bam files were normalized using the reads per genome coverage (RPGC) 
normalization method (Ramírez et al., 2016). BigWig or bedgraph format was used 
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for publicly available datasets. Graphpad 6.0 was used for bar and scatter plots, R 
3.5.1 was used for volcano and box plots, NMF package (0.21.0) was used for 
heatmaps and Inkscape 0.92 was used to assemble layouts. 
vi. Data availability 
All raw and processed data generated during this thesis project are made available 
under the accession number GSE132514 on the Gene Expression Omnibus (GEO) 
platform and the access token can be provided the reviewers upon request. The same 
applies to tables of DMPs, DB H3K27ac peaks and DEGs as well as R scripts. 
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RESULTS 
A. E2 deprivation leads to a global epigenetic-mediated down-
regulation of enhancers 
E2 deprivation is a well-established approach to study genome-wide response to 
ligand-dependent activity of ER. It is also a widely exploited in vitro model that 
mimics the molecular mechanisms behind aromatase inhibitor treatment used in 
clinical settings. Here I assess the impact of strict E2 deprivation on genome-wide 
DNAm, histone acetylation and gene expression using an optimised culture protocol 
of ER positive cell line MCF-7 (considered as the “workhorse” for studying ER-
positive breast cancer) for a total duration of 14 days. 
1. E2 deprivation leads to hypermethylation of ER-dependent 
enhancers 
i. Genome-wide methylation 
The following section was written in an effort to give a comprehensive view of the 
bioinformatic processing steps and differential analysis behind this work. Please refer 
to the first section of Material and Methods for a complete view on the experimental 
design (p.26).  
Preprocessing and normalisation 
To analyse the effect of E2 deprivation and re-stimulation, samples in biological 
triplicates (see experimental design, Figure 7) were processed on an 850k array. The 
experimental design was summarised in the form of a table necessary for the further 
statistical analysis to which I will refer to as pdata (Table 5). The variables of interest 
are ‘treatment’ (CTR, E2D and ReSt) and ‘time’ (d0, d4 and d14) as well as the 
concatenation of these two, designated as ‘group’ 
Table 5. Summary of samples and different variables used in the subsequent analysis (referred 
to in the script as pdata) 
Sample name barcode treatment time group sentrix ID sentrix position 
CTR_D0_1 201533580011_R01C01 CTR d0 CTR_d0 201533580011 R01C01 
CTR_D0_3 201533580011_R08C01 CTR d0 CTR_d0 201533580011 R08C01 
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CTR_D0_2 201533580015_R05C01 CTR d0 CTR_d0 201533580015 R05C01 
CTR_D4_1 201533580011_R04C01 CTR d4 CTR_d4 201533580011 R04C01 
CTR_D4_2 201533580015_R02C01 CTR d4 CTR_d4 201533580015 R02C01 
CTR_D4_3 201533580015_R07C01 CTR d4 CTR_d4 201533580015 R07C01 
E2D_D4_1 201533580011_R02C01 E2D d4 E2D_d4 201533580011 R02C01 
E2D_D4_2 201533580015_R01C01 E2D d4 E2D_d4 201533580015 R01C01 
E2D_D4_3 201533580017_R07C01 E2D d4 E2D_d4 201533580017 R07C01 
CTR_D14_1 201533580011_R05C01 CTR d14 CTR_d14 201533580011 R05C01 
CTR_D14_2 201533580015_R06C01 CTR d14 CTR_d14 201533580015 R06C01 
CTR_D14_3 201533580017_R02C01 CTR d14 CTR_d14 201533580017 R02C01 
E2D_D14_1 201533580011_R06C01 E2D d14 E2D_d14 201533580011 R06C01 
E2D_D14_2 201533580015_R03C01 E2D d14 E2D_d14 201533580015 R03C01 
E2D_D14_3 201533580015_R08C01 E2D d14 E2D_d14 201533580015 R08C01 
Rest_D14_1 201533580011_R03C01 ReSt d14 ReSt_d14 201533580011 R03C01 
Rest_D14_3 201533580011_R07C01 ReSt d14 ReSt_d14 201533580011 R07C01 
Rest_D14_2 201533580015_R04C01 ReSt d14 ReSt_d14 201533580015 R04C01 
After linking the pdata table and the raw data (.idat), samples were assessed for their 
quality. Median signal intensities for both methylated and unmethylated probes 
clustered together and all samples were well beyond the accepted intensity threshold 
(Figure 12). Based on these, all samples met the quality requirements and therefore 
they were all kept in downstream analysis. 
Figure 12. Quality control of samples based on array signal intensity. 
 
Next, I checked the distribution of total DNAm data. The methylation array 
technology is expected to show a bimodal distribution, as the probes have been 
purposely designed in functional genomic regions that are usually highly or lowly 
methylated (Figure 13). At this stage, for each of the 18 samples there are 866091 
available probes. 
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Figure 13. Distribution of DNAm levels before normalisation 
 
I then applied to all samples a functional normalisation (funnorm) (Fortin et al., 
2014), a method that normalises the signal based on some control probes that are not 
meant to measure biological signal but rather batch effects related to inter-array 
variability and bisulphite conversion. As a result, the global DNAm distribution is 
more homogeneous across samples (Figure 14A). For downstream analysis, it was 
also important to log-transform betas (M-values), as this process centres data around 0 
while rendering the distribution more normal-like and hence more usable by standard 
statistical methods (Figure 14B). I removed a list of probes that was predicted in silico 
to hybridise to more than one genomic location (n=43254) (McCartney et al., 2016) as 
well as probes that had no signal in at least one sample (n=207), ending with 822693 
working probes. 
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Figure 14. Distribution of beta and M-values after Functional Normalisation 
In order to check for potential batch effects affecting the variability between samples, 
a principal component analysis was performed (Figure 15). None of the known 
variables were contained in the first principal component but treatment and time 
variables were the only two variables significantly explaining the second principal 
component (Table 6). Although multiple batch correction functions exist, we decided 
to proceed without batch correction to avoid inflating differences due to our limited
sample size (Rødland et al., 2015). 
Figure 15 Proportion of variability explained from 10 first principal components 
 
Table 6. Significance of variables explaining 5 first principal components (p-values of 
Wilcoxon and Kruskal-Wallis tests for one level and multilevel variables respectively). 
Variable PC1 PC2 PC3 PC4 PC5 
sentrix 0.161 0.477 0.144 0.018 0.526 
sentrix_position 0.297 0.576 0.752 0.931 0.243 
A B
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treatment 0.164 0.037 0.17 0.054 0.743 
time 0.395 0.001 0.661 0.166 0.288 
group 0.169 0.008 0.53 0.133 0.372 
 
E2-deprivation leads to time-increasing hypermethylation 
To determine whether E2-deprivation has an impact on DNAm, we compared E2D to 
CTR groups, not considering ReSt group. We used two approaches to test this:  
Model (a) 
a model where the effect of treatment was contrasted (CTR vs E2D) and where 
the effect of time was taken into account (d0, d4, d14)  
# pdata corresponds to sample variables table above 
# mvals are the normalised M-values 
design <- model.matrix(~as.factor(treatment) 
                       +as.factor(time), 
                       data=pdata) 
fit <- lmFit(mval, design)   
 
The comparison of E2D (n=6) against CTR (n=9) revealed a total of 2978 DMPs, the 
majority of which were hypermethylated in E2D (Model (a)). The lambda value, 
which is a statistical measure of inflation4, as well as the shape of the qq-plot indicate 
that the p-values obtained for the E2D DMPs are relatively inflated (Figure 16).  
Table 7. DMPs in response to E2-deprivation over time (reference: CTR and d0) (FDR=0.05) 
 E2D d14 d4 
Hypo 745 241 0 
NotSig 819715 822293 822693 
Hyper 2233 159 0 
 
                                                
4 Method for calculation found here : 
 https://stats.stackexchange.com/questions/110755/calculate-inflation-observed-and-
expected-p-values-from-uniform-distribution-in 
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Figure 16. QQ plot observed against expected p-values of DMPs resulting from the 
comparison of CTR vs E2D (λ=1.84) 
 
A second observation was that time in culture also had an effect on DNAm and 
yielded 400 DMPs (d0 vs d14). The differences between the first and the last time 
point ranged from -32% to 23% Δβ. However, out of these 400 DMPs, only 9 were 
overlapping with the DMPs associated to the E2D treatment, indicating that the effect 
of treatment and of time were barely confounded (Figure 17). 
Figure 17. Overlap of DMPs associated to treatment and those associated to time. 
 
 
Model (b) 
a model where E2D and CTR were compared within each time point separately 
(’group’: concatenation of treatment and time variables).  
pdata$group <- relevel(pdata$group, ref = "CTR_d4") 
design <- model.matrix(~as.factor(group), 
                      data=pdata) 
fit <- lmFit(mval, design) 
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and 
pdata$group <- relevel(pdata$group, ref = "CTR_d14") 
design <- model.matrix(~as.factor(group), 
                       data=pdata) 
fit <- lmFit(mval, design)   
 
For the second analysis, we performed the differential analysis between CTR and 
E2D within each timepoint based on the assumption that if there is an effect of time in 
culture on DNAm, then this effect should be equivalent within the same timepoint. 
Therefore, two regression models were ran for each time point d4 and d14 comparing 
every time CTR and E2D in triplicates, omitting the CTR at d0. 
Table 8. DMPs in response to E2-deprivation on d4 (reference: CTR_d4 in contrast to 
E2D_d4) (FDR=0.05) 
 CTR_d0 CTR_d14 E2D_d14 E2D_d4 
Hypo 0 0 5661 0 
NotSig 822693 822693 804857 822692 
Hyper 0 0 12175 1 
 
Table 9. DMPs in response to E2-deprivation on d14 (reference: CTR_d14 in contrast with 
E2D_d14) (FDR=0.05) 
 CTR_d4 CTR_d0 E2D_d14 E2D_d4 
Hypo 0 48 802 0 
NotSig 822693 822493 818843 822689 
Hyper 0 152 3048 4 
 
The comparison of CTR and E2D at d4 revealed only one DMP while at d14, the 
same comparison revealed 3850 DMPs. This suggests that the effect of deprivation is 
mostly visible on d14. This is also reflected in the qq plots corresponding to the 
comparisons that were stratified by day (Figure 18).  
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Figure 18. QQ plot showing the inflation of p-values of the comparison E2D vs CTR (A) at 
d4  (λ=0.64) and (B) at d14 (λ=2.15) 
 
Model (a) vs (b) 
Unlike the model (b), the model (a) accounts for the effect of time and allows 
capturing differences that are consistently visible already at d4. In addition, as the 
inflation factor λ was smaller and the number of samples used in the comparison was 
larger in the first model (model (a)), we decided to perform all downstream analyses 
with DMPs obtained from the first model and to apply a 10% Δβ cutoff. This cut-off 
narrowed down the amount of DMPs to a total of 1014 with a pronounced majority of 
hypermethylated DMPs (n=952, hyperDMPs) against only 62 hypomethylated DMPs 
(hypoDMPs) (Figure 19). The model (a) also revealed a limited effect of time on 
DNAm that did not seem to be confounded to the effect of treatment.  
A B 
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Figure 19. Distribution of hyper- (hyperDMPs) and hypomethylated (hypoDMPs) for 
different cut-offs at d14 (Δβ) 
 
Figure 20. (A) Schematic representation of the experimental design. MCF-7 were cultured in 
control (CTR, green arrows) and E2-deprivation conditions (E2D, orange arrows) for 4 and 
14 days. (B) Heatmap of 10%Δβ DMPs obtained in response to E2-deprivation. 
 
E2-deprivation leads to hypermethylation of enhancers 
In the previous section we observed that E2-deprivation leads to a majority of 
hypermethylation events that became more prominent with time (Figure 19, Figure 
20). We next sought to examine if these changes are related to any particular 
functional elements. For this, we analysed the genomic features that overlapped with 
the DMPs and we observed that, compared to the distribution of all probes on the 
850k array, the hyperDMPs were mostly found in genomic regions distant from both 
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promoters and CpG islands (these elements often coincide) and were greatly enriched 
in intronic and especially in open sea contexts (Figure 21A and Figure 21B.). In 
contrast, hypoDMPs, represented by low number of DMPs, were not significantly 
enriched in any particular feature and were not further considered in this study.  
In order to further investigate potential function of these DNAm changes, we 
overlapped the positions of DMPs with publicly available histone ChIP-seq data. 
Among best-characterised histone marks are H3K4me1 and H3K4me3, which are 
location marks for enhancers and promoters respectively, and H3K27ac and 
H3K27me3, that are more dynamic in response to cellular and environmental stimuli 
distinguishing active from repressed regions, respectively. This analysis showed that 
hyperDMPs were significantly enriched in both H3K4me1 and H3K27ac marks 
(79.0% and 27.9%, respectively), which suggests that hypermethylation occurs in 
putative active regulatory regions (Figure 21C). In contrast, we observed that 
hyperDMPs were depleted (14.2%) in H3K4me3 marks, while no hyperDMPs were 
found in H3K27me3 (Figure 21C). To further characterise the functional context of 
the hyperDMPs, we overlapped the DMPs with ChromHMM 5  annotations of 
predicted chromatin states in MCF-7 (Taberlay et al., 2014). In this way, we 
confirmed that the non-promoter regions in which hyperDMPs are enriched could be 
likely enhancers, as hyperDMPS were significantly represented in enhancer and 
transcribed regions (49.8% and 14.9%, respectively), whereas they were lowly 
represented in promoter, CTCF-bound or repressed regions (1.9%, 0.8% and 0.0%, 
respectively) (Figure 21D). These results show that the increase in DNAm in response 
to estrogen deprivation mostly occurs within regulatory regions in introns that contain 
enhancers. 
                                                
5  ChromHMM is a software based on a hidden Markov model using multiple 
variables to assign functional chromatin states to genomic regions (Ernst and Kellis, 
2012). For this, different epigenomic datasets are used as input, mainly ChIP-seq but 
also DNAse-seq and NOMe-seq. 
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Figure 21. (A) Genomic features distribution and (B) CpG density of hypermethylated DMPs 
(hyperDMPs, n= 952)), all 850k CpG probes (n=866836) and hypomethylated DMPs 
(hypoDMPs, n=62). (C) Fold-enrichment of DMPs overlapping with publicly available 
histone ChIP-seq data and (D) ChromHMM annotations originated from MCF-7 cells 
(Taberlay et al., 2014). Asterisks (*) mark significant enrichments (p< 10e-5, Fisher test). 
Distributions and enrichments are shown for DMPs with ≥10% Δβ.  
 
Hypermethylation associated to estrogen deprivation occurs predominantly in 
lowly and partially methylated locations 
We observed that initial DNAm levels at sites that become hypermethylated had 
already low to intermediate methylation levels prior to E2 deprivation. More 
precisely, DNAm levels measured at d0 of the experiment ranged 40% and 71% (1st
and 3d quartile) with an average of 55% (Figure 22). This is in line with past studies 
showing that intermediate levels of DNAm are also associated with regulatory 
elements (Nothjunge et al., 2017; Stadler et al., 2011). 
C D
A B 
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Figure 22. Distribution of DNAm levels of DMPs before E2-deprivation (CTR-d0 replicates 1 
to 3) 
ii. Validation 
To further validate the above changes in DNAm, I replicated experiments by 
repeating E2 deprivation in two independent assays but also by using two alternative 
methods to inhibit ER signalling: by (i) silencing of ESR1 transcription and (ii) 
antagonist-mediated ER inhibition (being used in latter section of the thesis). 
Biological validation of E2 deprivation  
The E2 deprivation assay was repeated in two independent experiments where MCF-7 
were deprived for 7 and 9 days (experiment 1 and 2, respectively) after which the 
DNAm of several top DMPs was measured by pyrosequencing. There was a visible
increase of DNAm in time among all tested CpG sites (Figure 23). Intermediate 
DNAm levels at d0 were also observed in these assays. 
 RESULTS  
 55 
Figure 23. DNAm levels measured after 7 days (exp1) and 9 days (exp2) of E2 deprivation. 
DNAm was measured by pyrosequencing and is shown as average ± SD of triplicates. The 
effect of treatment was evaluated using a Mann-Whitney test. 
 
 
Silencing ESR1 gene expression 
Finally, siRNA targeting ER’s transcript, namely ESR1, was used as an alternative to 
reduce the activity of ER. The levels of ESR1 transcripts were efficiently knocked-
down by 92.6% 5 days after the transfection (Figure 24). The efficiency of knock-
down was also likely translated at the level of ER protein, since the expression of 
GREB1, TFF1 and PGR – that are canonical ER targets – was also strongly down-
regulated in the same samples, even in presence of E2 in the medium (Figure 24).  
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Figure 24. Expression of ESR1 and ER targets after 5 days after siESR1 transfection. Data 
shown as average ± SD of triplicates. Significance was tested using a Mann-Whitney test. 
 
Once the efficiency of the ESR1 knock-down was confirmed, I analysed DNAm of 
several CpG sites that were found hypermethylated in response to E2 deprivation. 
Five days after knock-down, we observed an increase of average DNAm ranging from 
6.7% to 13.8% for three CpG sites matching probes from the 850k array (Figure 25). 
The sequencing window of the probe cg13374172 allowed us to capture the DNAm of 
a CpG site 10bp downstream of the 850k CpG site and interestingly its DNAm was 
not affected as much as its neighbouring CpG (Figure 25, last panel). Although 
changes appeared statistically significant and are in line with the DNAm changes 
observed in the E2 deprivation assay, this result should be interpreted with caution 
due to the limited sample size.  
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Figure 25. DNAm levels measured after 5 days of siRNA targeting ESR1 transcripts. DNAm 
was measured by pyrosequencing and is shown as average ± SD of triplicates. The effect of 
treatment was evaluated using a Mann-Whitney test. 
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2. Histone deacetylation in enhancers in response to E2 deprivation 
The analysis of genome-wide DNAm revealed that E2 deprivation lead to the 
hypermethylation of CpGs located in intragenic enhancers. The latter were identified 
using two approaches: their occurrence within regions having a high ratio between 
H3K4me1 and H3K4me3 and their overlap with enhancers that were previously 
annotated with ChromHMM in MCF-7 (Jozwik et al., 2016; Taberlay et al., 2014). 
Yet, the physical overlap with enhancers does not provide us with sufficient 
information on the degree of activity of these regulatory elements. Multiple methods 
have been established with time to measure enhancer activity, such as sequencing of 
enhancer RNAs, RNA Pol II binding or H3K27ac marks (Franco et al., 2017; De 
Santa et al., 2010). Based on the above, we sought to find whether the E2D DMPs 
were enriched within H3K27ac marks but also if H3K27ac levels varied in response 
to E2 deprivation.  
i. ChIP of histone marks in proximity to DMPs 
For this, we conducted a pilot experiment where MCF-7 were deprived for 10 days 
followed by measuring three histone marks in proximity (<100bp) of top DMPs 
detected earlier. We chose H3K4me1 to verify if DMPs were in an enhancer context 
as well as H3K27ac and H3K27me3, two histone marks indicating enhancer 
activation and repression, respectively (Figure 26). H3K4me1 and H3K27ac marks 
were detected in the proximity of all four DMPs tested while H3K27me3 levels were 
low. In addition, H3K27ac signal was on average higher in CTR group in contrast to 
E2D. As a positive control of active enhancer, we used a GREB1 enhancer known to 
be active under regular E2-containing culture conditions for MCF-7 (Jozwik et al., 
2016). Consistent with the picked regions, H3K27ac signal was enriched and was on 
average higher in CTR in comparison to E2D in this control region, although not 
significantly, while H3K27me3 was barely detected. In contrast, a higher H3K27me3 
signal was detected in the control that mapped within the promoter of a gene that is 
neither expressed nor contains any DMPs. Together, the absence of H3K27me3 and 
the presence of H3K27ac signal suggest that the panel of picked DMPs is likely 
located in proximity to enhancers that are seemingly more active in CTR than in E2D 
conditions. 
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Figure 26. ChIP of H3K4me1, H3K27ac, H3K27ac marks and IgG in CTR at d11 and E2D at 
d10 across four top DMPs (title: 850k probe name). qPCR data was normalized over input 
DNA and presented as an average ± SD of duplicates. Data was analysed using a Wilcoxon 
ranked test within each histone mark. 
  
 
 
ii. ChIP-seq of active histone mark H3K27ac 
In order to have a genome-wide view of specific histone mark specific for active 
enhancers, MCF-7 were cultured in presence and absence of E2 for 4 and 14 days, 
and H3K27ac profiles were measured with ChIP-seq. Narrow peaks were called 
against a CTR input and the IDR method was used to keep highly consistent peaks 
between the biological duplicates. This yielded 31,090 consistent peaks for CTR, 
32,995 peaks for E2D and 36,214 peaks for ReSt. The higher number of IDR-filtered 
peaks in the ReSt and E2D group simply reflects the higher read homogeneity 
between duplicates of these groups (PC1, Figure 27A). The comparison of CTR vs 
E2D led to the identification of 3053 differentially bound (DB) regions (|log2FC| >1, 
FDR <0.05) (Figure 27B) the large majority of which showed a lower signal in E2D 
cells compared to CTR cells (Figure 28). Total H3K27ac peaks were evenly detected 
across promoter, intronic and intergenic regions, but the DB regions were located in a 
similar genomic context to DMPs, that is, in intronic and intergenic regions (42.9% 
and 41.1%, respectively, Figure 29A). An overlap with the ChromHMM annotation 
revealed that 44.0% of these peaks were found in enhancer regions (Figure 29B). 
Furthermore, under E2-stimulated conditions, 25.9% of DB peaks co-localised with 
ER binding events and almost half of the them (11.2% of total DB peaks) overlapped 
with E2-dependent ER peaks measured by Swinstead et al. (Swinstead et al., 2016)  
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(examples shown in Figure 30). Taken together these results point to an inactivation 
of enhancers that could be in part mediated by direct ER binding. 
Figure 27. PCA of normalized read counts (A) for all the binding sites and samples, and (B) 
for DB H3K27ac regions (FDR <0.05) specifically for CTR and E2D contrast 
       
Figure 28. Global decrease of histone acetylation expressed in log2 normalised reads in DB 
H3K27ac regions in CTR and E2D (|log2FC| >1, FDR <0.05). DB peaks were separated in 
decreasing and in increasing acetylation in response to E2 deprivation. 
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Figure 29. (A) Genomic features distribution of ENCODE H3K27ac peaks (n=33,631), 
H3K27ac IDR thresholded peaks for CTR and E2D at d14 (n=31,090 and n=32,995) as well 
as for the DB peaks between the two groups (n=3053, |log2FC|>1, FDR <0.05). (B) Overlap 
of DB H3K27ac regions with ChromHMM annotations originated from MCF-7 cells 
(Taberlay, 2014). 
 
Figure 30. Genome browser snapshot of H3K27ac normalised ChIP-seq reads in CTR and 
E2D conditions, ER and FOXA1 ChIP-seq reads in E2-treated and untreated MCF-7 
(*GSE72249, Swinstead et al., 2016) and FOS ChIP-seq (°GSE105734, ENCODE Project 
Consortium et al., 2012). 
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3. Gene expression mostly decreases with E2 deprivation 
To further characterise the genome-wide impact of ER activity on gene regulation, we 
performed an analysis of the transcriptome (RNA-Seq) of CTR and E2D conditions at 
d4 and d14 in the same samples used for the methylome analysis. Resulting 
expression data served two main purposes at this stage of the project:  
• Measuring the global effect of E2 deprivation in stricto sensu and assessing 
the concordance of our protocol with other studies that were focused on ER-
dependent transcription 
• Finding specific targets that may explain the observed epigenetic changes  
 Overall 14,617 genes were expressed at detectable levels across all samples and the 
comparison of treatments (CTR vs E2D), after adjusting for time, revealed 5466 
differentially expressed genes (DEGs) with a FDR = 0.05. The addition of an absolute 
cut-off of log2FC >1 limited the number of DEGs to 547, 71.1% of which were 
downregulated in response to E2 deprivation (Figure 31A). In a meta-analysis of ER-
regulated genes in MCF-7 cell line, Stanislawska-Sachadyn et al. identified a set of 24 
genes that are commonly de-regulated in response to different exposure times and E2 
concentrations (Stanislawska-sachadyn et al., 2016). Of these, 19 DEGs were also 
significantly deregulated in this study, and 17 changed in the expected direction. In 
addition, among the top DEGs, I identified genes known to be directly upregulated by 
ligand-activated ER through their promoter-enhancer interactions, such as GREB1, 
TFF1 or PGR, supporting that our cell culture model is in line with the previously 
reported impact of inactivation of ER (Figure 31B) (Fullwood et al., 2009). The 
expression of these particular genes was also validated by RT-qPCR (Figure 32).  
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Figure 31. (A) Distribution of –log10(p-values) of differentially expressed genes (DEGs) 
according to log2 fold-change of expression.  Coloured dots represent down- and up-regulated 
DEGs with an absolute log2(FC) >1 (blue and red) based on a FDR <0.05 (dashed horizontal). 
Genes that were differentially expressed with an absolute log2(FC) <1 are coloured in dark 
gray. (B) Heatmap showing top 50 DEGs (FDR <0.05) for CTR and E2D at d4 and d14.  
 
Figure 32. Technical validation of selected genes from the RNA-seq by quantitative RT-
qPCR. The effect of treatment was tested using a Mann-Whitney test (* p <0.05; ** p <0.01). 
Results are shown as the average of triplicates ± SD. 
 
To explain the observed DNAm and histone acetylation changes I next tested whether 
the expression of ERFs was affected by the ligand-mediated decrease of ER activity. I 
therefore focused on the expression levels of a collection of 426 ERFs (unpublished 
data) and found that E2 deprivation increased the expression of HDAC9 (log2FC 
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=2.1) and decreased the expression of PADI4 and TET2 (log2FC =-1.5 and -0.8 
respectively). HDAC9 is a histone deacetylase and is part of the family of HDACs 
that are commonly associated to gene repression, PADI4 is a transcriptional co-
activator, and TET2 is an enzyme catalysing CpG demethylation and is also 
associated to gene activation (Figure 33A) (Plass et al., 2013; Zhang et al., 2011). The 
same genes were also significantly differentially expressed in the same direction in 
MCF-7 that were treated with ICI 182,270 for 4 and 14 days, a drug that is known for 
inducing ER protein degradation and consequently down-regulation of ER signalling
(Figure 33B). This further consolidates the possibility that the deregulation of these 
ERFs is mediated by ER binding. Taken altogether these results show that E2 
deprivation leads to a global gene down-regulation and to the deregulation of specific
ERFs that are in line with the loss of enhancer activity. It is noteworthy that TET2 
absolute expression levels were much higher in contrast to HDAC9 or PADI4 that had 
a low baseline expression, suggesting that a change in expression of TET2 could have 
a more consequent impact at the protein level compared to the other two transcripts. 
Another interesting observation across all tested ER targets was that the expression 
changes were not noticeable between d4 and d14 unlike DNAm changes that were 
clearly time-dependent.  
Figure 33. Gene expression of epigenetic remodeling factors HDAC9, PADI4 and TET2 in 
response to (A) E2 deprivation found (RNA-seq, n=3, FDR < 0.05) and (B) to ICI inhibition 
(RT-qPCR, Mann-Whitney CTR vs ICI, * p <0.01), for 4 and 14 days. Data of ICI treatment 
are shown as the average of triplicates ± SD. 
 
B. Integration of ER-dependent epigenetic and transcription changes 
At this stage of the study we have in our hands three datasets (methylome, H3K27ac 
ChIP-seq and transcriptome) that were all produced in ER-expressing breast cancer 
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cells that were deprived of E2 for 14 days. The changes in DNAm profile (850k data) 
and the binding profile of the active chromatin mark H3K27ac (ChIP-seq data) 
suggested that the activity of ER-dependent enhancers decreases in response to E2 
deprivation. In parallel, the transcription-wide data obtained by RNA-sequencing 
showed that the expression levels of 71% of DEGs decreased. In this section, we 
aimed to integrate these datasets in an attempt to find common molecular 
denominators associated to ER that may drive these epigenetic and transcriptional 
changes. 
1. Associations of epigenetic and transcriptional changes 
i. Co-occurrence of epigenetic changes 
In the onset of this study, we observed that a part of DMPs obtained in response to E2 
deprivation were significantly overlapping with publically available H3K27ac peaks 
in MCF-7 (27.9% of hyperDMPs; 1.5x compared to 850k overlap, see p.51), which 
suggests that differential DNAm occurs in active chromatin regions. I therefore 
wanted to see if this overlap was also significant in our experimental setting. For this, 
I first overlapped DMPs with all filtered and IDR-thresholded H3K27ac peaks 
obtained under CTR conditions. 10.9% of E2-deprivation DMPs overlapped regions 
carrying H3K27ac marks in CTR conditions (Table 10). This was lower to the 
expected overlap that I observed earlier where 27.9% DMPs overlapped with 
ENCODE H3K27ac ChIP-seq data (see p.51), that was obtained from MCF-7 in 
similar culture condition to CTR in this study. One plausible explanation for this 
observation is that this specific ENCODE peak file contained peaks reaching up to 
42kb, while I applied a maximal peak size of 1.5kb. According to this, there is a 
possibility that the first overlap of DMPs with H3K27ac peaks was over-estimated 
and thus advocate that more filters to publically available datasets need to be applied.  
I then focused specifically on the 3053 DB regions and found only 3 DMPs 
overlapping within 500bp away from the centre of these H3K27ac peaks (Table 10). 
A technical consideration that potentially contributes to the limited overlaps could be 
that the ChIP-seq and 850k arrays were performed not only in two independent 
experiments but also in two different batches of MCF-7. Nevertheless, after 
expanding the genomic window of both CTR and DB H3K27ac peaks, the percentage 
of overlapping DMPs considerably increases in an absolute way but also in 
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comparison to the percentage of overlap of total available CpG sites (Table 10). This 
led us to the hypothesis that DNAm and H3K27ac levels at defined locations may be 
regulated by common chromatin remodelling complexes, and that these complexes do 
not necessarily operate in short genomic windows but rather in distant cis locations 
through chromatin looping events.  
Table 10. Overlap of DMPs with H3K27ac peaks 
DMPs (n=1014) 850k (n=866,836) 
H3K27ac 
window size+ 
CTR d14 
(n=31,090) 
DB peaks 
(n=3053) 
CTR d14 
(n=31,090) 
DB peaks 
(n=3053) 
1 kb 10.9% 0.3% 10.7% 0.3% 
10 kb 34.9% 5.0% 27.1% 1.8% 
100 kb 84.9% 23.0% 65.1% 11.0% 
+ Total genomic window evenly centred on peak summit. 
ii. Correlation of DNAm and gene expression 
Although the overlap between DEGs and genes and carrying DMPs was not 
significant, I performed a more in-depth correlation analysis matching all DMPs and 
DEGs, this time with no differential cut-offs. I first correlated DNAm and expression 
within CTR and E2D samples (n=12) and found 666 DMPs that both negatively or 
positively correlated with expression (n=342 and 324, respectively) (Spearman |ρ| > 
0.67, FDR <0.05, Figure 34). After filtering for highly variable DMPs and DEGs 
(|log2FC|>1 and |Δβ|>10%), only 51 DMPs strongly correlated – mostly negatively – 
to differential expression. These 51 DMPs match altogether to 40 genes that were 
identified in the pairwise overlaps above. Among these genes we found GREB1 and 
PKIB, both of which are common ER targets (Figure 35). Nevertheless, in order to 
find any causal relation between DNAm and expression, one would need to 
specifically target the DNAm at one of these sites for instance with the help of dCas9-
Dnmt3a systems (Liu et al., 2016) and check if the expression changes. 
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Figure 34. Correlation of differential methylation and expression. Significantly correlating 
DMPs and DEGs (Spearman |ρ| > 0.67, FDR < 0.05) are depicted in pink and red points 
indicating correlating an absolute |log2FC|>1 and |Δβ| >0.1. DMPs matching non-
differentially expressed genes are shown in grey.
 
Figure 35. Correlation of DNAm of cg10612997 and cg26207870 and gene expression 
correlation to their closest gene (GREB1 and PKIB, respectively). 
 
iii. Overlaps of nearest gene  
Because the correlation of epigenetic and transcription changes within the same
genomic location was limited, I tested if E2 deprivation had an impact in genes that 
were deregulated in at least two out of the three measured readouts, independently of 
the direction of changes (DNAm, H3K27ac and gene expression). For this, genomic 
regions carrying DNAm and H3K27ac changes were firstly annotated with the nearest 
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gene, which sometimes was more than 1Mb away from DMPs and DB H3K27ac. 
However, picking the nearest proximal gene in terms of genomic distance is a safe 
approach and commonly used to match regulatory elements such as enhancers and 
gene expression (Corces et al., 2018). Next, I performed pairwise overlaps between 
genes corresponding to each differential dataset and tested if the common genes were 
significantly enriched compared to the background overlap of all available genes. 
Genes containing or mapping closely to a DMP were significantly likely to also map 
near to a DB H3K27ac peak (FC=2.5x, Fisher p= 8.7x10-30, Figure 36). This was also 
the case for DEGs that were also significantly enriched in DB H3K27ac by 2.5x 
(Fisher p= 7.6x10-21, Figure 36). Nevertheless the number of genes being altered at all 
three levels was extremely low and this low overlap was mainly driven by the limited 
overlap of DEGs and genes containing a DMP. 
At this point, we found that the global down-regulation in gene expression is in line 
with the observed general increase of DNAm and loss of histone acetylation marks. 
Nevertheless, the overlap between DEGs and genes containing DMPs or DB 
H3K27ac peaks in cis was relatively low compared to the total number of shared 
genes. Considering that most of these epigenetic changes in enhancers have a 
functional impact, we reasoned that they may not necessarily regulate the expression 
of the nearest gene but rather resulting from dynamic binding of TFs associated to 
ER. Together these results suggest that under E2-stimulated conditions, ER shapes 
epigenetic marks both directly and indirectly while ER deactivation leads to a global 
decrease in active enhancer marks and to a major down-regulation in gene expression. 
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Figure 36. Pairwise overlaps of DEGs and genes that map to nearby DMPs or DB H3K27ac 
peaks. For fold-enrichment significance, a Fisher test against only genes present in both 
differential datasets were considered as background. 
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2. Identification of ER key cofactors in E2-dependent gene regulation 
The results obtained so far show that E2 deprivation leads to DNA hypermethylation 
and a decrease in histone acetylation of enhancers and that these changes are partially 
associated with gene expression down-regulation in cis. As it is widely accepted that 
E2 deprivation leads to reduced ER binding and time of residence, it is conceivable 
that E2 deprivation could also affect the binding of ER cofactors to DNA (He et al., 
2018; Swinstead et al., 2016; Zwart et al., 2011). This is indeed the case for p300, 
SRC1/2/3 and JUN whose binding can decrease after E2 deprivation but it is not for 
FOXA1 whose binding is barely affected in the same context (Glont et al., 2019; He 
et al., 2018; Swinstead et al., 2016; Theodorou et al., 2013). Based on the above, we 
hypothesised that the observed epigenetic changes are the result of ER’s altered 
cistrome and we sought to explore the TFs that may coregulate these events. 
For this, I first conducted an enrichment analysis of transcription factor binding sites 
in the proximity of DMPs, DB H3K27ac and DEGs using the ChEA database 
(Kuleshov et al., 2016). For each type of dataset, a list of TF that significantly bind to 
the associated genes was obtained. The overlap of the enriched TF lists revealed that 
in addition to expected enrichment of ERα and ERβ binding events, binding of other 
TFs (including ZNF217, TFAP2C and GATA3) were found enriched among the 
genes that map near DMPs and DB H3K27ac regions (Figure 37). These findings 
support functional and physical protein interactions between these TFs and ER that 
have been reported in previous studies (Mohammed et al., 2013; Nguyen et al., 2014). 
Interestingly, when considered separately, the up-regulated fraction of DEGs was 
enriched for binding sites of PRC2 members SUZ12 and EZH2, consistent with the 
fact that when ER is active, it can also actively repress gene expression (Figure 38) 
(Ariazi et al., 2017). TF binding sites within the down-regulated fraction of DEGs – 
that are active when ER is induced by E2 – were also enriched in genes containing 
DMPs and DB H3K27ac. This suggests that common TFs are involved in the ER-
dependent maintenance of these genes’ epigenetic marks and their expression. 
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Figure 37. Enrichment of TF binding on the nearest genes to DMPs (n=829 genes), the 
nearest genes to differentially bound H3K27ac marks (n=577, ≥2 peaks per gene name) and 
DEGs (n=547).  Numbers represent the amount of TFs whose binding was significantly 
enriched across the different sets of genes (FDR <0.05). Enrichment of TFs originating from 
experiments performed in MCF-7 cells are highlighted in red in the upper right panel (ChEA 
2016, Kuleshov et al., 2016).  
 
Figure 38. Enrichment of TF binding down- and up-regulated genes (log2FC <-1 and log2FC 
>1, FDR <0.05, n=381 and n=166). The enrichment score is the combination of log(p-value) 
and Z-score of expected rank (ChEA 2016, Kuleshov et al., 2016). Bars surrounded with a 
black line indicate datasets that are originated from MCF-7 cells.  
 
Although informative, the ChEA database is limited by the number of datasets it 
contains and provides a broad picture of TF enrichment based on gene names rather 
than specific genomic sequences. Therefore, to detect putative DNA-binding TFs in a 
more unsupervised approach, we searched for enriched TF motifs in proximity of E2 
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deprivation-mediated DMPs and DB H3K27ac by performing a de novo motif 
analysis. Our first observation was the lack of the majority of the motifs 
corresponding to the above-identified TFs, including the canonical ER-binding motif, 
suggesting that ER and these particular TFs do not bind directly on or in close 
proximity of DMPs and DB H3K27ac regions. Instead motifs matching AP-1 and 
FOX TFs, known to be main ER cofactors, were enriched in proximity to both DMPs 
and DB H3K27ac regions (Figure 39). Based on these findings and the knowledge of 
reported ER cofactors, I overlapped a set of publically available TF ChIP-seq datasets 
in MCF-7 cultured in conditions equivalent to CTR (Table 4) with DMPs, DB 
H3K27ac marks and DEGs identified in this study. The significantly enriched TFs 
were then split in three categories: 1) TFs that are both highly enriched and 
overlapping with top hits, 2) TFs that were highly enriched but overlapped with low 
to middle fraction of top hits and 3) TFs that were lowly enriched but overlapped a 
large fraction of top hits.  
FOS, a major AP-1 component, was the only TF that matched the criteria of the first 
category as it was enriched by 9.1x and overlapped with nearly 1/3 of DMPs. FOS 
enrichment in DB HK27ac regions and DEGs was lesser (<2.0x) but overlapped a 
large fractions of regions. ER, FOSL2, p300, AHR and NCOA3 met the criteria of the 
second category as they were also importantly enriched across all differential datasets 
but with moderate and low percentages of overlap (Figure 40). Inversely, FOXA1, 
GATA3 and ZNF217 matched the third category as they were moderately enriched in 
DMPs and DB HK27ac regions although they highly overlapped all differential 
datasets. This is in line with the preferential binding of these factors in proximity to 
active marks or active genes. At last, a de novo motif search in the regions bound by 
ER and its cofactors (namely FOXA1, FOS, TFAP2C, p300, ZNF217, GATA3, and 
AHR) revealed an important occurrence of AP-1 and FOX motifs in all cofactors’ 
binding regions (Figure 41).  
Together, these findings emphasise the importance of ER tethering and suggest that 
AP-1 plays a central role in the maintenance of DNAm and H3K27ac marks, thereby 
orchestrating chromatin changes through enhancer regulation. It is also noteworthy 
that the expression of all the above-mentioned TFs remained unchanged after E2 
deprivation, which hints towards a regulation in cis rather than trans. 
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Figure 39. De novo motif analysis performed on DMPs (top 4 hits shown) and DB H3K27ac 
(|FC| ≥ 1, top 2 hits shown) obtained after 14 days of E2 deprivation. The enrichment is the 
result of the percentage of the motif occurrence in target sequences over random background 
genomic sequences. The motif search was expanded over a 500bp-window for DMPs and a 
1kb-window for DB H3K27ac peaks.  
,
Figure 40. Overlap of DMPs, DB H3K27ac regions and DEGs with a collection of publicly 
available TF ChIP-seq datasets in MCF-7. Fold-enrichement was calculated as the fold-
change between the percentage of binding overlap within a differential set of hits over the 
percentage of TF overlap within the total of 850k CpGs, the H3K27ac regions in CTRs at d14 
(IDR peaks) and the total fraction of genes that were expressed in the RNA-seq. Published 
datasets used for the overlaps are enlisted in Table 4. 
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Figure 41. De novo motifs detected in regions bound by ER and known cofactors. 
Finally, DNAm levels were visibly lower in CpG sites that overlap with binding sites 
of ER and its cofactors (Figure 42). This suggests that TF binding could have a link to 
proximal DNAm possibly by passively preventing DNMT-mediated methylation of 
DNA by spatial exclusivity or inversely, by active recruitment of TET that contribute 
to gradual demethylation of DNA. 
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Figure 42. Average DNAm distribution in CpG sites bound by TFs before E2 deprivation at 
d0. 
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C. Partial reversibility of epigenetic and expression changes after ER 
re-activation 
We mentioned earlier that E2 deprivation and ER antagonists are used as an in vitro 
proxy to application of aromatase and ER inhibitors in the clinical setting. Such 
treatments are applied for a defined period of time after which ER signalling can 
resume. Nevertheless, some patients were found to fail responding to the treatment or 
even relapse that is frequently associated with development of endocrine resistance to 
the initial treatment. This led to the hypothesisis that some irreversible molecular 
changes may occur during this process. Having this in mind, I asked whether the 
observed epigenetic and transcriptional changes could be reversed or precluded from 
further increasing if the E2 deprivation interrupted or ER inhibitors removed.  
1. Partial reversibility of epigenetic and transcription changes in 
response to E2 re-stimulation 
i. DNA methylation 
To test potential reversibility of E2 deprivation specific epigenetic changes, MCF-7 
that were E2-deprived for 4 days were re-exposed to E2 for 10 days (ReSt) before 
being harvested and processed on the 850k platform (Figure 43A). Data was pre-
processed and normalised concomitantly to CTR and E2D (as described on p.43). I 
analysed the data using three approaches of linear regressions models: 
a) a model taking both into account treatment and time as separate variables, 
comparing ReSt to  CTR and E2D across all normalised probes, 
pdata$treatment <- relevel(pdata$treatment, ref = "ReSt") 
pdata$time <- relevel(pdata$time, ref = "d14") 
design <- model.matrix(~as.factor(treatment) 
                       +as.factor(time), 
                       data=pdata) 
fit <- lmFit(mval, design) 
b) a model where ReSt was compared against CTR and E2D only within 
timepoint d14 and 
pdata$group <- relevel(pdata$group, ref = "ReSt_d14") 
design <- model.matrix(~as.factor(group), 
                       data=pdata) 
fit <- lmFit(mval, design)   
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c) a model where ReSt was compared against CTR and E2D on d14, and where 
we included only probes corresponding to the 10% Δβ hypermethylated DMPs 
obtained in the CTR vs E2D analysis.  
pdata$group <- relevel(pdata$group, ref = "ReSt_d14") 
design <- model.matrix(~as.factor(group), 
                       data=pdata) 
fit <- lmFit(mval_hyperDMPs, design) 
 
Briefly, for the first model, the ReSt group (n=3) was compared to CTR (n=9) and 
E2D (n=6), taking time into account in the linear regression model. No DMPs were 
found between CTR and ReSt but there were 51 DMPs when comparing ReSt and 
E2D data (Table 11).  
Table 11. DMPs in response to E2 re-stimulation (reference: ReSt and d14) (FDR=0.05) 
 CTR E2D d0 d4 
Hypo 0 0 159 266 
NotSig 822693 822642 822293 821825 
Hyper 0 51 241 602 
For the second model, we assumed there is no effect of time in culture and we 
compared ReSt against CTR and E2D only within d14 and for all probes on the array 
(n=3 for each group). Again no DMP was found between the comparison between 
ReSt and CTR but 679 DMPs were found between ReSt and E2D (Table 12). This 
suggests that ReSt methylome is closest to the methylome of CTR samples rather than 
E2D samples. 
Table 12. DMPs in response to E2 re-stimulation on d14 (reference: ReSt_d14) (FDR=0.05) 
 CTR_d14 E2D_d14 
Hypo 0 23 
NotSig 822690 822014 
Hyper 0 656 
 
Finally, when I compared ReSt to the other two groups using only the 952 
hyperDMPs obtained from the E2 deprivation, a minor fraction of DMPs was 
hypomethylated in CTR compared to ReSt. This suggests that there was a gain in 
DNAm at d4 that persisted in several CpG sites after 10 days of E2 re-stimulation. On 
the other hand, the large majority of DMPs was statistically different between ReSt 
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and E2D, indicating that the gain of DNAm was largely precluded after E2 re-
stimulation.
Table 13. DMPs in response to E2 re-stimulation only among E2D-responsive 
hypermethylated DMPs with 10% Δβ on d14 (FDR=0.05). 
 CTR_d14 E2D_14 
Hypo 20 0 
NotSig 932 7 
Hyper 0 945 
Globally all three models detected no or few DMPs between the CTR and the ReSt. 
On the other hand, the comparison of ReSt to E2D did reveal DMPs in all models, but 
never as many as were found in the CTR vs E2D comparison, suggesting the ReSt 
group was not as different from the E2D group as was the CTR group. In addition, 
overall DNAm in the hyperDMPs was seemingly higher in the ReSt group as visible 
on Figure 43B and C. Validation with pyrosequencing recapitulated the trend with the 
majority of CpGs in ReSt group showing a return to DNAm levels equivalent to those 
of CTR with the exception of the CpG matching the cg04210444 probe where DNAm 
levels of ReSt were closer to E2D group (third panel, Figure 44). 
Figure 43. Hypermethylation due to E2 deprivation is in majority reversed or precluded after 
E2 re-stimulation (A) MCF-7 were deprived of E2 for 4 days, after which they were re-
stimulated with E2 for 10 days (ReSt, blue dashed line). (B) Heatmap and (C) boxplot of 
hypermethylated DMPs (FDR < 0.05; > 10% Δβ) in response to E2-deprivation for CTR, 
E2D and ReSt at d14. 
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Figure 44. Technical validation of DNAm levels. Pyrosequencing analysis of indicated DMPs  
in CTR, E2D and ReSt  (green, orange and blue, respectively) . 
 
ii. Histone acetylation 
Next I aimed to compare the ReSt H3K27ac peaks to those of the CTR by focusing on 
the DB peaks that were common to the DB peaks of the CTR vs E2D comparison. We 
found that 347 out of 3053 E2-responsive DB H3K27ac peaks were significantly 
lower in ReSt compared to the CTR group and their signal was equivalent to that of 
the E2D group (Figure 45). Despite the 10-day E2 re-stimulation, the histone 
acetylation levels in certain regions did not return to initial acetylation levels. We then 
overlapped these regions with publically available H3K37me3 peaks and found 
virtually no overlaps. The non-recovery of H3K27ac signal in certain regions and the 
complete absence of H3K27me2 marks suggest a possible shift from active to primed 
chromatin that cannot be inversed by solely by the addition of E2. 
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Figure 45. Partial recovery of H3K27ac signal after 4 days of E2 deprivation followed by 10 
days of E2 re-stimulation (A) H3K27ac signal in log2 normalised reads of 347 peaks that 
were significantly different in both CTR vs ReSt and CTR vs E2D comparisons. (B) Genome 
browser snapshot of H3K27ac normalised ChIP-seq reads in CTR, E2D and ReSt conditions
at d14 (chr1:24701801-24702801)  
    
iii. RNA expression 
At the level of gene expression, I found that after E2 re-stimulation (ReSt) the 
majority of DEGs that were down-regulated in E2D globally returned to their 
expression levels with the exception of 6 DEGs whose expression was significantly 
different from CTR (CTR vs ReSt, FDR < 0.05, |log2FC| > 1). Two of the DEGs that 
did not recover their initial expression level were TRAF2 and NCK Interacting 
Kinase (TNIK) and Matrix Metallopeptidase 13 (MMP13) that are an inducer and a 
target, respectively, of AP-1 (Figure 46). The expression of canonical ER targets 
GREB1, TFF1 and PGR fully recovered (Figure 47). 
Figure 46. Gene expression of AP-1 inducer TNIK and target gene MMP13 in E2 deprived 
and re-stimulated conditions on day 14 (RNA-seq, CTR vs ReSt, FDR < 0.05, |log2FC| > 1) 
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Figure 47. Changes in ER target expression6. The effect of E2D and ReSt treatment was 
measure by quantitative RT-qPCR and was tested using a Mann-Whitney test (* p <0.05; ** p 
<0.01). Results are shown as the average of triplicates ± SD. 
 
 
2. Validation of partial reversibility of DNAm and transcription 
following removal of ER antagonist 
To further validate the reversibility of DNAm changes using an independent
approach, I inhibited ER activity with antagonist ICI 182,780 for 4 days and 14 days 
(ICI), while the re-activated group was treated with ICI for 4 days, after which the 
drug was removed and DNAm analysed 10 days thereafter (ReAc) (see Figure 9). For 
this, 4 CpG sites were selected that were among the top DMPs from the E2-
deprivation analysis that met the criteria for enhancer-like genomic features, and 
DNAm was measured in a targeted way using pyrosequencing. Similar to E2-
deprivation, I observed that ICI 182,780 treatment increased DNAm, and in addition 
DNAm changes were of larger amplitude in comparison to the response to E2-
deprivation (Figure 48). Interestingly, DNAm levels between ReAc and CTRs were 
not significantly different, although the restoration of initial DNAm was not complete 
for all tested sites, indicating that reactivation of ER following the antagonist removal 
leads to partial and slow reversal of DNAm changes. In addition, expression of TNIK, 
but not that of MMP13, decreased with ICI treatment and did not fully recover with 
the removal of the inhibitor (Figure 49). This result further supports that AP-1 can be 
indirectly deregulated in an ER-dependent manner. Just like for the E2 deprivation, 
the expression of HDAC9, PADI4 and TET2 studied earlier (Figure 33) fully 
recovered after ICI removal (Figure 50). Globally, these results show that epigenetic 
changes are largely reversible or precluded from increasing following E2 re-
stimulation. Nevertheless, a smaller fraction of the observed changes does not 
       
6 CTR and E2D samples are the same as those used in Figure 32 
RESULTS 
82
recover, even if the expression of ERFs does, suggesting the existence of an estrogen-
dependent epigenetic memory. 
Figure 48. DNAm dynamics of top DMPs (title: 850k probe id) following DMSO treatment 
for 4 and14 days (CTR, green), ICI 182,780 treatment for 14 days (ICI, orange), and 4 days of 
ICI 182,780 treatment followed by 10 days of DMSO (ReAc, blue dashed). Results are shown 
as the mean of triplicates with 95% of C.I. Significance of changes was calculated at d14 
using a Mann-Whitney test (*p < 0.05).  
 
Figure 49. Gene expression of AP-1 inducer TNIK and target gene MMP13 in following 
treatment (ICI) and removal (ReAc) of ICI (RT-qPCR, Mann-Whitney * p < 0.05 and ** p < 
0.01).  
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Figure 50. Gene expression of epigenetic remodelling factors HDAC9, PADI4 and TET2 in 
response to ER inhibition and reactivation by ICI 182,780, for 4 and 14 days7. Data of ICI 
treatment are shown as the average of triplicates ± SD. 
                                                
7 CTR and ICI samples are the same as those used in Figure 33 
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DISCUSSION 
In this study, we bring novelty to the field by adapting a cell culture protocol for 
studying E2 deprivation and re-stimulation in stricto sensu in  and by using the latest 
methylation array that allows a genome-wide interrogation of methylation states, 
including a comprehensive panel of enhancers (Moran et al., 2016). We saw that 
prolonged E2 deprivation and re-stimulation result in time-dependent DNAm changes 
and in histone acetylation modifications across diverse genomic regions, many of 
which occur within enhancer elements. This is the first study that comprehensively 
characterized DNAm and histone acetylation at enhancers in response to a sequential 
inactivation and re-activation of ER signalling. These observations are consistent with 
and extend previous studies showing that ligand-mediated ER activity has an impact 
on the epigenome, through mechanisms that likely involve tethering of ER by other 
TFs (Fleischer et al., 2017; Kininis et al., 2007). 
1. The cell line model 
In order to study the sequential effect of estrogen deprivation and re-stimulation, we 
aimed to implement a cell culture model that can address strictly the effect of E2. So 
far the existing protocols of E2 deprivation consist in depriving cells from all 
components that are removed during the process of FBS charcoal stripping. In 
addition, our protocol offers an appropriate compromise in terms of duration of 
treatment that was sufficiently long to cause noticeable molecular changes and also 
short enough to prevent cells from losing their sensitivity to estrogen. This latter issue 
is linked to the nature of the cell line itself. MCF-7 is a cancer cell line that was 
established 1973 and has become ever since the most widely used cell model in the 
context of ER-positive breast cancer research (Soule et al., 1973). Being a cancer cell 
line, it is not surprising that plenty of clones have been derived from the initial culture 
ever since its establishment, one of which, HTB-22, is commercially available by 
ATCC in passage no less than 147. The “age” of the cell line, as well as the large 
variety of MCF-7 subclones contribute at least in part to reported discrepancies 
between studies and lack of reproducibility. Unfortunately, this is also reflected at the 
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level of large consortia such as ENCODE, that used 2 different sources of MCF-78, 
although the HTB-22 clone was used in most cases. All these considerations 
underscore the necessity to use consensus models and protocols within the scientific 
community, especially for widely used cell lines such as MCF-7. 
Because of all the limitations related to the current models, we believe that our 
approach to culturing MCF-7 offers a robust and reproducible alternative that 
addresses the effect of one single molecule and that it consolidates the knowledge of 
the molecular biology of ER. Indeed, the direction of the changes in expression of ER 
target genes in response to E2 deprivation, ER inhibition and siRNA indicates that our 
protocol recapitulates the expected changes that are caused from the deregulation of 
ER signalling. Our protocol approach could easily be applied in the context of other 
molecules. 
2. Hypermethylation and histone deacetylation of ER-dependent 
enhancers 
We showed that DNAm levels consistently increase whereas H3K27ac signal 
decreases in a particular set of enhancers using different molecular methods and in 
total three different cell culture approaches that effectively down-regulate ER activity: 
• E2 deprivation which reduces dramatically ER binding events without 
affecting the protein expression 
• siRNA targeting ER’s transcript which reduces the amount of ER available at 
the protein level 
• treatment with ICI that leads to the reduction of ER at the protein level 
through promoting its degradation 
The common point to all of the above treatments is that ER binding decreases in a 
consequent number of sites.  ER’s reduced binding in response to these treatments is 
extensively shown in literature and this is also evident in this study through the 
deregulation of canonical and newly discovered target genes. Depending on the 
approach, epigenetic changes were detectable as early as 4 days and became 
                                                
8 In majority ATCC, HTB-22 subtype was used for standard protocols. ECACC 
MCF-7 subtype (catalog#: 86012803) was used for E2 deprivation and re-stimulation 
protocols. Information found on www.encodeproject.org/documents/ under growth 
protocols, filtered for MCF-7. 
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progressively more pronounced pointing towards an active adaptation of the 
epigenetic landscape. 
i. Epigenetic changes occur in enhancers and reflect TF binding  
Thanks to the genome-wide coverage of 850k BeadChip array and H3K27ac ChIP-
sequencing, we were not only able to measure numerous significant changes of 
epigenetic modifications but also to observe that these changes were significantly 
enriched in enhancers. The latter were identified mostly with the use of publically 
available annotations (ChromHMM) and histone marks (enrichment in H3K4me1 and 
H3K27ac + depletion in H3K4me3 and H3K27me3 marks). Furthermore, both DMPs 
and DB H3K27ac (86.6% and 84.0% respectively) were markedly enriched in introns 
and in intergenic regions. Particularly for DNAm, the occurrence of DMPs in 
enhancers was reinforced through the observation that initial DNAm levels at these 
DMPs were low to intermediate, which is characteristic of cis-regulatory elements 
away from promoters (Nothjunge et al., 2017; Stadler et al., 2011). If projected in 
time, one can think of intermediate levels of DNAm as a snapshot of the transition 
between unmethylated and methylated states and vice versa. Such a mechanism is 
consistent with previously described cyclical switches in DNAm and H3K27me3 that 
are believed to rapidly fluctuate in a matter of hours (Angrisano et al., 2016; Métivier 
et al., 2008). Métivier et al. observed extreme fluctuations in DNAm at the level of 
TFF1 promoter after E2 re-stimulation of α-amanitin synchronised MCF-7 and the 
authors associated this to ER cyclical binding. Swinstead et al. also observed “pulsed” 
binding of ER at a nucleus-wide scale using a newly developed microscopy technique 
that allows measuring the time of residence of a TF on DNA (Swinstead et al., 2016). 
Together, these observations led to postulate that these epigenetically variable 
enhancers could be shaped by dynamic E2-mediated ER binding.  
In addition, the overlap between genes with expression and epigenetic changes in 
proximal cis-regulatory regions was limited (Figure 36). We therefore turned to an 
analysis of the TF network of ER given that their binding to ER-dependent enhancers 
is also affected by E2 deprivation, and consequently could impact the epigenetic 
landscape. In line with the limited overlap between ER binding and differential 
epigenetic marks, our analysis of enriched binding motifs of TFs did not identify ER 
motifs in proximity to DMPs and DB H3K27ac peaks. On the contrary, AP-1 and 
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FOX motifs were enriched by 6.5x and 3.9x in proximity of DMPs and by 3.9x and 
1.7x in DB H3K27ac regions. These motif enrichments were associated to important 
overlaps of FOS binding – an AP-1 component – and DMPs while both FOS and 
FOXA1 highly overlapped with DB H3K27ac regions (Figure 40). Based on these 
observations, it is conceivable that AP-1 regulates DNAm of CpG sites that are 
proximal to its binding sites in the context of an E2-induced system. Remarkably, AP-
1 and FOX motifs were consistently and highly enriched at all binding sites of all 
established ER cofactors investigated (namely FOXA1, FOS, TFAP2C, p300, 
ZNF217, GATA3, and AHR) (Figure 41). FOXA1 and GATA3, followed by FOS 
binding, were also significantly enriched at functional enhancers (defined by an 
expression–methylation quantitative trait loci analysis) that distinguish ER-positive 
from ER-negative BC subtypes (Fleischer et al., 2017). This raises the possibility that 
the specific mechanisms are conserved between cell line models and clinical samples. 
These results are consistent with the frequency by which ER regulates genomic 
regions through a tethering mechanism with other cofactors, rather than through direct 
binding (Carroll, 2016; Mohammed et al., 2013). 
ii. Cross-talk of ER, ER cofactors and epigenetic regulatory factors 
However, all these ER and cofactors dynamic binding events cannot directly modify 
epigenetic marks. The edition of the latter is in fact catalysed by ERFs, including 
different enzymes from the DNMT, TET, HAT and HDAC families. Previous studies 
have established that DNA hypermethylation and histone deacetylation at gene 
promoters are associated with gene silencing (Weber et al., 2007). In contrast, there is 
less data on the role of epigenetic changes at enhancer regions, and the specific 
mechanisms that underlie specific targeting of enhancers for hypermethylation is 
unclear. It is known that specific chromatin interactions, involving DNAm dynamics, 
are abolished and are replaced by others in response to ER activation and inactivation 
(Fullwood et al., 2009; Hsu et al., 2010; Taberlay et al., 2014). Indeed, in some 
instances DNAm deposition is directed by TF-mediated DNMT recruitment, whereas 
in others DNAm can be the result of the lack of TF occupancy which exposes these 
sites to DNMT complexes that have an affinity for unmethylated CpGs (Hervouet et 
al., 2018; Stadler et al., 2011). The disengagement of ER and its cofactors from 
chromatin induced by E2 deprivation, could make unmethylated CpG sites susceptible 
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to methylation, which is consistent with the observation that methylated DNA 
represents a default state (Singh et al., 2013).  
In an alternative, although not mutually exclusive scenario, E2 deprivation-associated 
hypermethylation may be the result of reduced demethylating activity at enhancers 
involving TET methylcytosine dioxygenases. This could happen through the 
reduction of TETs’ expression and/or through a decreased recruitment of TET2 on 
enhancers. Interestingly, we observed both after E2 deprivation and ICI inhibition a 
decrease in expression of DNA demethylase TET2 (Figure 33). The possibility of a 
double mechanism explaining hypermethylation is supported by a recent study 
showing that ER not only recruits TET2 on ER-dependent enhancers but it also 
positively regulates TET2 expression in response to E2 induction, and that TET2 
knock-out leads to hypermethylation of enhancers (Wang et al., 2018).  Given that 
AP-1 peaks and motif were enriched in proximity to E2-dependent DMPs, it is 
possible that AP-1 could also interact with TETs as it was already shown for FOXA1 
(Yang et al., 2016; Zhang et al., 2016). Considering that ER and AP-1 often interact 
as part of the same complex (He et al., 2018; Jeffy et al., 2005; Lupien et al., 2010), 
our results support the idea that AP-1 may play a bridging role between ER and TET2 
at the level of enhancers, therefore maintaining DNAm levels stable under E2-
stimulated conditions.  
Similarly, the occurrence of AP-1 and FOX motifs and the enrichment of 
acetyltransferase p300, FOS and FOXA1 binding sites at DB H3K27ac regions 
reinforce previously reported ER-mediated maintenance of histone acetylation 
recruitment of p300, AP-1 and FOXA1 to enhancers (Allison et al., 2016; Jeffy et al., 
2005; Vierbuchen et al., 2017; Zwart et al., 2011). Furthermore the decrease of 
H3K27ac levels after E2 deprivation is consistent with a decrease of enhancer 
activity. This finding, together with the absence of overlap with H3K27me3, which is 
characteristic of repressed and poised chromatin states, suggests that the identified 
enhancers may switch from an active to a primed state in response to E2 deprivation 
(Caglio et al., 2017; Calo and Wysocka, 2013). Priming of ER-dependent enhancers is 
further supported by the intermediate levels of DNAm which seem to play also a role 
in this mechanism (Elliott et al., 2015; Mahé et al., 2017; Sharifi-Zarchi et al., 2017). 
In this regard, we propose that the reduced binding of ER could open the opportunity 
to HDACs to act. It is in fact plausible that the decrease of H3K27ac signal could be 
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related to both an increased accessibility to HDACs but also the observed increase of 
HDAC9 expression, although there is little evidence of a direct relationship between 
this class IIa HDAC and H3K27ac deacetylation (Delcuve et al., 2012; Petrie et al., 
2003). 
Based on these findings we propose that the decreased activity of ER and potentially 
that of its cofactors renders ER-dependent enhancers prone to DNA hypermethylation 
and histone deacetylation, ultimately tipping the balance from an active to a primed 
enhancer configuration (Hervouet et al., 2018; Skvortsova et al., 2019). The decrease 
of TET2 and the increase of HDAC9 expression that was observed in response to both 
E2 deprivation and ICI inhibition could contribute to the above mechanism, although 
further studies are needed to test this hypothesis. 
3. A putative mark of endocrine resistance 
i. Partial reversibility of epigenetic changes 
Our data also showed that the majority of DNA hypermethylation induced by E2 
deprivation could be prevented or even reversed when the cells were re-stimulated 
with E2 after a period of deprivation (Figure 43, Figure 44). This trend was even more 
pronounced after ER inhibition by ICI treatment (Figure 48). However, we cannot 
rule out the possibility that the duration of deprivation followed by re-stimulation was 
not sufficiently long to observe a full reversal of DNAm changes, or on the opposite, 
to generate statistically detectable changes pointing towards a non-reversible 
mechanism. Indeed, we found that DNAm differences were not statistically different 
at d4 (Table 8). Nevertheless, DNAm levels of the ER-dependent hyperDMPs were in 
average higher in the re-stimulated group compared to controls (Figure 43C) which 
cast the doubt on whether DNAm levels are fully reversible or simply prevented from 
increasing after E2 re-stimulation. As for H3K27ac, there was a subset of DB peaks in 
the ReSt group that carried a significantly lower H3K27ac signal compared to CTRs 
and that was in fact as low as the signal of E2Ds (Figure 45). This strengthens the 
possibility that there is a fraction of enhancers that loses their activity in a long-term 
manner although longer E2 deprivation and re-stimulation should be applied to 
confirm a permanent switch-off. 
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ii. All lights on AP-1 
Independently of the enrichment of AP-1 binding within ER’s cistrome, the E2 re-
stimulation and ICI removal assays both lead us on a second track involving AP-1. 
Indeed, we observed that the expression of two AP-1-related genes, TNIK and 
MMP13, remained significantly lower following E2 re-stimulation. TNIK is a kinase 
that activates c-Jun N-terminal kinase (JNK1) in primary human B-cell which in turn 
activates the AP-1 complex (Shkoda et al., 2012). Interestingly, it was shown that 
phosphorylation and JNK1 genomic binding on both on ER and AP-1 binding sites 
can occur partially in response to E2-induced ER signalling (Sun et al., 2012). Our 
results show that TNIK expression is regulated by ER, likely through E2-dependent 
binding on the only putative enhancer of TNIK (Figure 51). In addition, no changes in 
the expression of AP-1 component were observed which is in favour of a non-
genomic, yet ER-dependent, regulation of AP-1 (data not shown). This opens the door 
to a missing link between ER and AP-1 that is worth exploring. Little is known about 
the upstream regulation of MMP13 in the context of breast cancer cells besides the 
fact it can be a target of AP-1 (Datar et al., 2015). High protein levels of MMP13 
were detected in more aggressive and metastatic breast tumours that is neither in in 
direct relation to endocrine resistance nor in line with the very low expression levels 
measured in MCF-7 (Kotepui et al., 2016).  
In agreement with a scenario of non-reversible mechanisms, some studies showed E2 
deprivation and ER inhibition can lead to endocrine resistance and this has often been 
attributed to an overexpression or a redistribution of AP-1 binding sites (He et al., 
2018; Lupien et al., 2010; Malorni et al., 2016). In simple words, AP-1 is not 
recruited on ER-dependent sites following ER inactivation and that leads to the partial 
redistribution of the pool of AP-1 complexes on other binding sites. We think that the 
epigenetic changes we observed occur in these common ER/AP-1 binding sites and 
that when cells are E2-re-stimulated, a part of these sites is no more accessible to the 
complex. A study by Fujimoto et al supports this possibility by showing that DNAm 
on CpG sites that are adjacent to the binding motif of AP-1 can prevent AP-1 from 
binding in vitro (Fujimoto et al., 2005). Taken together with our findings on AP-1 
enrichment in proximity to DMPs may add a new piece to the puzzle of endocrine 
resistance, further studies with longer durations of treatment are needed to 
substantiate these findings. One would need to apply our protocol for longer periods 
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and with regular sample collections to capture the switch towards endocrine resistance 
setting of the methylome, 
Figure 51. E2-dependent binding of H3K27ac and ER on TNIK enhancer (2nd intron, 
chr3:170,971,567-170,988,176) 
 
iii. Proposition of a novel molecular mechanism  
Based on all our results, we propose a model in which ligand-activated ER and its 
cofactors orchestrate an intricate interaction in cis between promoters and a panel of 
epigenetically dynamic enhancers (Figure 5). Under continuous E2 exposure, AP-1 
contributes to the maintenance of balance between TET2 and DNMT proteins in order 
to keep DNAm at intermediate levels in intronic enhancers while, in collaboration 
with p300 and FOXA1 proteins, AP-1 preserves histone acetylation in distal 
enhancers and thereby maintains gene expression. In response to E2 deprivation, 
“decommissioning” of ER and by extension that of TET2 and AP-1 at ER-dependent 
enhancers would open the opportunity to DNMTs to methylate CpG sites in the 
proximity of AP-1 binding sites thereby impeding AP-1 binding upon E2 re-
stimulation. The lagging recovery of DNAm and histone acetylation levels at certain 
enhancers could be the result of the partial re-distribution of AP-1 binding sites away 
from ER-responsive regions. In parallel to this mechanism, the ER-mediated variation 
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of TET2, HDAC9 and TNIK expression levels could contribute indirectly to the 
enhancers’ shift from an active to a primed state. 
Figure 52. Proposed mechanistic model for shift from active to primed chromatin state in 
response to E2 deprivation and re-stimulation. In this model the reduction of ligand-
dependent ER activity leads to an AP-1 and FOXA1 mediated increase of DNAm and 
decrease of H3K27ac and transcription. The reversibility of these changes is partial. This 
model include findings of this thesis work and integrates prior knowledge of ER-dependent 
chromatin and TF interactions (ENCODE Project Consortium et al., 2012; Swinstead et al., 
2016; Wang et al., 2018).  
 
4. The necessity to re-evaluate long term E2 deprivation and ER 
inhibition models in the context of research on endocrine resistance 
In the optimisation phase of the antagonist exposures, I discovered that ER drug 
inhibition did not work on cells cultured in CSS-medium in presence of E2 (Figure 8). 
At first, I thought that the inhibitors’ concentration could not antagonise E2 at the 
ligand-binding domain of ER but it has been shown that both ICI and TAM can bind 
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ER with a similar affinity to that of E2 (Kuiper et al., 1997). Furthermore, if the 
concentration of the antagonists was indeed a problem, the concentration of E2 in 
non-stripped serum – which can also range around 10nM (Sikora et al., 2016) – 
should also prevent the inhibitors’ action. Yet this was not the case which brought me 
to follow a second lead. During serum stripping most lipophilic molecules are 
removed and as a result the polarity of the solution changes and becomes more 
hydrophobic (Sikora et al., 2016). In addition to this, bio-tech providers also point that 
serum composition can affect cell membrane permeability and therefore the transfer 
of lipids into the cell9. Besides this, the chemical structures of E2, ICI 182,780 and 
tamoxifen are different enough to have different hydrophilic features as the three 
molecules have low, yet different water solubility (Figure 53, E2: 3.6 mg/L10; ICI: 
9.53x10-6 mg/L11, TAM: NA). Finally, as ICI 182,780 and tamoxifen are commonly 
used drugs in the clinical setting, their chemical and physical features are well studied 
and it is known that they are highly lipophilic molecules (Jordan, 2007; Park et al., 
2018). Based on all the above, it is conceivable that these drugs are not chemically 
available to the cells when they are added in CSS medium. A solution to test this 
would be to quantify the amount of the antagonists in the medium 24h after their 
addition in four groups as following: CSS+E2 medium and MCF-7 vs CSS+E2 
medium but no cells and equivalently regular-serum medium and MCF-7 vs regular-
serum medium and no cells. 
In 2015, Stone et al. showed that 6 months of E2 deprivation as well as individual ICI 
and tamoxifen treatments of MCF-7 lead to the hypermethylation of >15000 CpG 
sites in common that were importantly located in enhancers (Stone et al., 2015). 
However, the cells treated with the two inhibitors were in fact cultured in CSS 
medium. According to the above observation, it would not be impossible that the 
extensively inhibited cells underwent in fact the same treatment as E2 deprived cells. 
Furthermore, the acquisition of these DMPs was done by comparing the treated cells 
                                                
9 https://www.thermofisher.com/fr/fr/home/references/gibco-cell-culture-basics/cell-
culture-environment/culture-media.html 
10 National Center for Biotechnology Information. PubChem Database. Estradiol, 
CID=5757, https://pubchem.ncbi.nlm.nih.gov/compound/5757 (accessed on May 20, 
2019) 
11 National Center for Biotechnology Information. PubChem Database. Fulvestrant, 
CID=104741, https://pubchem.ncbi.nlm.nih.gov/compound/104741 (accessed on May 
20, 2019) 
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to a parental MCF-7 that seem not to have been cultured in parallel for an equivalent 
number of passages. Yet it has been shown repeatedly shown that MCF-7 gradually 
and spontaneously develop a loss of estrogen responsiveness which is translated into 
endocrine resistance and for biologically consistent results, MCF-7 should not be 
cultured for longer than 25 passages (Devarajan et al., 2002; Kleensang et al., 2016; 
Nelson, 2016). For all the reasons stated in this section and given the “popularity” of 
MCF-7 in the BC scientific community, it would be important to establish and follow 
standard guidelines of cell culture and why not turn to new normal-like ER-
expressing cell lines.  
Figure 53. Chemical structures of E2, TAM and ICI. 
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CONCLUSIONS 
• This study capitalises on our optimised cell culture protocol for studying 
estradiol deprivation and re-stimulation in stricto sensu combined with the 
latest methodologies for epigenomic profiling and extensive expertise for 
analysis and interpretation of omics and mechanistic data available in 
Epigenetics group and collaborating labs. 
• We show that E2 deprivation and re-stimulation result in time-dependent 
DNA methylation changes and in histone modifications across diverse 
genomic regions, many of which overlapped with enhancers. 
• Our RNA-seq and ChIP-seq data reinforced the notion that ER activity may 
orchestrate a broad transcriptional programme through regulating a limited 
panel of critical enhancers and that the E2-mediated epigenetic changes are 
likely involved in priming of enhancers. 
• ER activity regulates epigenetic marks on distant enhancers in an indirect 
way that involves the recruitment of a multitude of transcription factors and 
epigenetic regulatory factors. 
• The maintenance of these epigenetic marks at ER-dependent enhancers are 
likely to be the result of a balance between an active recruitment of activators 
and the passive repulsion of inhibiting factors. 
• While observed epigenetic changes induced by estrogen deprivation are 
largely reversible, some changes persist following a sequential E2 
deprivation and re-stimulation consistent with the existence of “epigenetic 
memory” of estrogen-dependent gene activity states. 
• Our enrichment analysis of TF binding and motif occurrence highlighted the 
importance of ER tethering mainly through two partner TF families, AP-1 
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and FOX, in the proximity of enhancers that undergo epigenetic 
reconfiguration. 
• Based on our results, we proposed a new mechanistic model in which ligand-
activated ER and its cofactors orchestrate an intricate interaction in cis and 
maybe trans between promoters and a panel of epigenetically dynamic 
enhancers.  
• Collectively our study provides entirely new information that constitutes a 
major advance in our understanding of the events by which ER and its 
cofactors mediate changes in DNA methylation and chromatin states at 
enhancers. 
• This new insight gained by our study opens new avenues for studying the role 
of the deregulated estrogen signalling in both breast cancer development and 
the mechanism underlying the “roots” of endocrine resistance that commonly 
develops in response to anti-estrogen therapy 
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